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ABSTRACT 
ANALYSIS OF THE BREAST CANCER PROTEOME 
BHATIA ICD, Lord RJ, Stanton PD 
Discipline of Surgery, University of Tasmania, Hobart 
PURPOSE 
The discovery of the oestrogen and her-2 receptor proteins paved the way for the 
subsequent development of adjunctive therapeutic options for the treatment of breast 
cancer. The advancement of proteomic technology has enabled the identification of 
such unique proteins differentially expressed in a range of disease states including 
breast cancer. It is our aim to use this technique to identify potential target molecules 
for future therapy. 
METHODS 
Breast cancer samples weighing 100mg were obtained from patients in Tasmania and 
Greece. Normal breast tissue was obtained as control from patients undergoing 
reduction mammoplasty. Sample preparation was performed using a sequential 
extraction protocol to yield two solutions per tissue sample. This was followed by 
two-dimensional gel electrophoresis and resultant gels analyzed using PDQuest 
software. 
RESULTS 
Quantitative analysis revealed a 5-fold increased expression of 54 spots and decreased 
expression of 20 spots in breast cancer versus normal tissue using solution 2 and 3 
extracted gel images. All such identified spots were located within pI (Iso-electric 
point) 6.0-8.2 and molecular weight 25-75kDa. Further detailed analysis enabled the 
identification of a number of spots showing differential expression by clinical stage 
including metastatic cancer, histological subtype, racial subgroup and amongst 
familial cancers. 
CONCLUSION 
The further characterization of identified spots will involve the exclusion of known 
markers using immunoblotting techniques with unknown spots subjected to mass 
spectrometric analysis or amino acid sequence determination. This approach may 
allow the identification of new diagnostic and/or therapeutic targets. 
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LIST OF ABBREVIATIONS 
ATM 	 Ataxia Telangiectasia Mutation 
BRCA-1 Breast Cancer-1 gene 
BRCA-2 	 Breast Cancer-2 gene 
DCC Deleted in Colon Cancer gene 
DCIS 	 Ductal Carcinoma in Situ 
DNA Deoxyribonucleic Acid 
DTT 	 Dithiothreitol 
EGFR Epidermal Growth Factor Receptor 
ESI-MS 	 Nanoelectrospray Ionization Mass Spectrometry 
FGF Fibroblast Growth Factor 
FISH 	 Fluorescent In Situ Hybridization 
GAP GTPase Activating Protein 
GDP 	 Guanosine Diphosphate 
GTP Guanosine Triphosphate 
HER 	 Human Epidermal Growth Factor Receptor 
HRT Hormone replacement therapy 
IARC 	 International Agency for Research on Cancer 
IEF Iso-Electric Focus 
IR-MALDI-MS 	 Infra-Red Matrix Adsorbed Laser Desorption Ionization 
Mass Spectrometry 
IPG 	 Immobilized pH Gradient 
LCM Laser Capture Micro-dissection 
LCIS 	 Lobular Carcinoma in Situ 
MALDI-TOF 	 Matrix Adsorbed Laser Desorption Ionization Time Of 
Flight 
NEPHGE 	 Non Equilibrium pH dependant Gradient 
Electrophoresis 
RNA 	 Ribonucleic Acid 
mRNA messenger RNA 
RHH 	 Royal Hobart Hospital 
SDS-PAGE 	 Sodium Dodecyl Sulphate- Polyacrylamide Gel 
Electrophoresis 
TBP 	 Tri-Butyl Phosphine 
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AIMS 
1. To elucidate the differential expression of proteins in 
cancerous breast tissue. 
2. To study racial differences in breast cancer, by the analysis 
of tumour samples from Tasmania and Greece. 
3. To identify protein spots that are associated with a 
metastatic phenotype of breast cancer, by the analysis of 
progressive clinical stage and axillary node tissue. 
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FOREWORD 
In Eugene Delacroix's painting c1830 titled "Liberty Leading the People", Liberty is 
represented as an inspiring, bare-chested woman at the front of battle, stirring the men 
around her to fight. 
It is our endeavour to study nascent breast tissue, malignant and benign, including 
those from different populations using protein biochemistry and proteomic 
technology. This subject has not been studied extensively, to date, using the above-
mentioned means. 
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1.0 LITERATURE REVIEW 
1.1 PATHOGENESIS 
There are a multitude of aetiopathological factors that need to be taken into account in 
order to establish a causal basis for this study. 
Geographical considerations 
Australia is one of the few countries in which cancer registration occurs on a national 
basis and data are obtained from multiple sources. The Menzies Centre for Population 
Health Research (Hobart, Tasmania) data indicate that the risk of developing any 
cancer by the age of 75 years is approximately 1 in 3 according to figures derived in 
1998 [1]. Cancer incidence generally increased with age and the highest incidences 
were found in the >60 year age groups. Of these prostate and lung cancers were most 
frequent in males and breast cancer in females [1]. Breast cancer, mentioned in the 
context of this study shall imply female beast cancer and not the much rarer condition 
of male breast cancer. 
In 1998, breast cancer accounted for 27% of all cancers diagnosed in the Tasmanian 
population [1]. 
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Figure!: Common cancers, 1998: number of cancers diagnosed in all females in Tasmania [1]. 
Deaths due to Breast Cancer featured prominently among cancer related deaths in 
Tasmania in 1998 (61 cases or 14% of all cancer related deaths) [1]. 
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Figure 2: Common causes of cancer related deaths, 1998: total number in all females  [1]. 
At a national level, the incidence and mortality of breast cancer can be compared. 
Data from the Australian Institute of Health and Welfare suggests that even on a 
national level breast cancer is the most commonly occurring cancer in females with a 
total national incidence of 10,096 cases of breast cancer cases in 1997 (27.8% of all 
new cancer cases) with a total mortality of 2,596 cases (17.4% of all cancer deaths) in 
the same year [2]. These figures correlate with those for Tasmania from the Menzies 
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Centre for Population Health Research. Interestingly, data also suggests a gradual 
increase of 2.1% per annum in incidence rates between the years 1992 and 1997 
whereas mortality rates have declined slightly by 1.6% per annum [2]. 
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Figure 3: Trends in age-standardized incidences and mortality rate for cancer of the breast, 
Australia, 1983-1998 [2]. 
Incidence and mortality figures gathered worldwide vary for a large number of 
reasons. These may be caused by differential risk factor exposure, genetic 
susceptibility, detection and treatment practices, and even coding and registration 
procedures. It is clear however, that Australia features prominently on the world stage 
in terms of breast cancer incidence. The second population group involved in this 
study is from Athens, Greece whose incidence figures are intermediate (84.4 per 
100,000 population in females of all ages). Breast cancer is largely a disease of 
affluent western societies such as the United States, Netherlands and Australia, and 
less common in countries such as Greece, Japan and Taiwan [2]. Some of these 
factors could be genetic in nature, but they are thought more likely to be 
environmental as shown by the fact that when migrants from low incidence locales 
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migrate to an area where the incidence is higher, they take on the higher incidence 
rates of their adopted nations. These factors are as yet undetermined but diet, 
reproductive patterns and nursing habits are thought to be involved [3-5]. We had 
chosen a differential analysis of tumours obtained from Greece to attempt to answer 
these questions. 
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Figure 4: Cancer incidence and mortality in Australia according to IARC 2002 [6]. 
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Figure 5: Cancer incidence and mortality in Greece according to IARC 2002 [6]. 
Genetics and family history 
There has been a great deal of interest in the genetic links predisposing an individual 
towards the development of cancer in the modern era. The risk of acquiring  a 
genetically linked breast cancer is said to be higher if one or more of the below 
mentioned variables are present. 
• A diagnosis of breast cancer before the age of 50 years. 
• A first degree relative who has been previously diagnosed with breast cancer. 
• A known inherited genetic defect in the family such as B RCA- 1, BRCA-2 or 
ATM. 
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Not surprisingly, most patients in our study group were in fact post menopausal. As 
such, in those who did display a family history, the significance is uncertain and 
hence did not warrant genetic testing. The specific inherited mutations account for 
only 5-10% of all breast cancers and of these the most pertinent are BRCA-1 and 
BRCA-2. 
• The BRCA-1 gene is located on chromosome 17q21 and predisposes to breast 
and ovarian cancer [7]. Like the p53 gene it is also a tumour suppressor gene 
and its product encodes a protein secreted from breast epithelium that inhibits 
cell growth after binding to cell surface receptors. It has been calculated that 
women with a BRCA-1 mutation have a 50% chance of developing breast 
cancer by the age of 50 years and an 80% chance by the age of 65 years. 
• The BRCA-2 gene is located on chromosome 13q12-13 and is also thought to 
be a tumour suppressor gene linked to breast but not ovarian cancer. It carries 
with it a similar lifetime risk although these tumours tend to have a better 
prognosis due to oestrogen receptor positive status. At this stage it is not 
entirely clear how mutations in these genes manifest in an increased 
predisposition to breast cancer, but there is evidence indicating that a ring 
protein (BARD-1) is required to interact with the BRCA-1 segment and that the 
BARD1-BRCA1 interaction is disrupted by mis-sense mutations indicating that 
BARD-1 may be involved in mediating tumour suppression by BRCA-1 [8]. 
• The Li-Fraumeni syndrome delineates a condition in which individuals inherit 
a germ line mutation in the p.53 tumour suppressor gene located on 
chromosome 17p13.1. Individuals with this inherited mutation show an 
increased susceptibility to develop a wide range of tumours including 
carcinomas, sarcomas, lymphomas and brain tumours. The condition accounts 
15 
for < 1% of breast cancers and is much less common than other inherited 
mutations [9]. In this syndrome, breast cancer appears in women under 40 
years of age and is more often bilateral than in the general population. 
• The syndrome of Ataxia Telangiectasia involves a gene located on 
chromosome 11q22 encoding a mutated protein kinase. The ATM gene plays a 
critical role in the repair of DNA damage. Patients with this syndrome display 
an increased susceptibility towards breast cancer directly and indirectly via the 
targeting of tumour suppressor genes such as BRCA1 and p53. However, 
while women with Ataxia Telangiectasia display an increased predisposition 
to breast cancer, an increased frequency of ATM mutations is not found in 
breast cancer [10]. 
Aside these, there are other factors that have a significant relationship with breast 
cancer and these include growth promoting factors such as the proto-oncogene c-erb 
B-2 (also called her-2, c-neu) and sporadic mutations in growth inhibiting factors such 
as the tumour suppressor genes, Rb (retinoblastoma) and p53 [9]. 
Environmental factors 
• Obesity — The relationship of obesity to the incidence of breast cancer is ill 
defined, however Trentham-Dietz et al have documented the greater incidence 
of breast cancer in the top quintile groups for height at age 20 years, recent 
weight and body mass index. In women who reached their highest adult 
weight at younger ages (<45 years), increasing weight loss since that age 
showed a reduced risk of post-menopausal breast cancer. However in women 
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whose highest adult weight was seen after the age of 45 years, this reduced 
risk after weight loss was not seen [11]. In addition researchers have found 
differences between cohorts of increasing adiposity for rates of recall, biopsy 
and cancer detection. Hunt KA et al found an increase in the rates of recall (p 
<0.0001), biopsy (p < 0.0002) and screen detected cancers (p < 0.015) as well 
as an increased median cancer size (p <0.02) and advanced stage at diagnosis 
(p = 0.046) [12]. However, these results are inferential at best. 
• Alcohol — The effects of alcohol in the causation of breast cancer are also ill 
defined. Some authors conclude that alcohol should be considered to be an 
established risk factor given the greater proportion of positive studies versus 
studies in which no causal link was identified [13]. 
• Smoking — The effects of smoking have been well documented to include a 
tumour initiating, mutagenic effect as well as, in relation to breast cancer a 
protective anti-oestrogenic effect. A confounding study documented by 
Manjer J et al has actually concluded that the incidence of breast cancer was 
higher in ex-smokers than it was found to be in current smokers or those that 
had never smoked. The age adjusted relative risk for all smokers was said to 
be 1.31 and in pre-menopausal smokers it was 1.57. The incidence of breast 
cancer was inversely related to the time period since quitting and was found to 
be highest in those that had given up 12 months prior to screening (RR=2.76) 
[14]. The relationship between breast cancer, smoking and the oral 
contraceptive pill would also need to be taken into account, although data to 
this effect is lacking. Clearly more studies need to be performed with this 
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relationship in mind even though the above study included a cohort of 10,902 
women. 
• Dietary fat intake — The relationship of dietary fat intake has been studied 
previously and results are difficult to interpret. Zemla B et al found no 
significant association with dietary fat intake when studying differences in 
incidence between native and migrant populations in Poland [15]. La Vecchia 
C et al studied various groups in Italy and found a significant inverse 
relationship of breast cancer with the intake of olive oil and other vegetable 
oils, but not with butter or margarine [3]. In China where the incidence of 
breast cancer is a fifth of that of the United States, modest associations were 
found by Yuan JM et al between the intake of unsaturated, mono- and 
polyunsaturated fats and breast cancer among two population groups 
(Shanghai and Tianjin) of varying incidence [4]. This group also displayed a 
strong inverse association with breast cancer and the intake of carotene, crude 
fibre and vitamin C. Thus, data on a relationship of breast cancer with dietary 
fat intake is conflicting and the results difficult to interpret. 
In addition to the above-mentioned variables, breast cancer incidence has tended to 
fluctuate in certain areas along with public awareness of the subject. This is of course, 
an indirect association and reflects increased participation in screening programmes. 
In 1974 nationwide public attention was created when the wives of the President and 
Vice-President of the United States were diagnosed with breast cancer and set out to 
undergo surgery. During this period there was a documented sharp rise in attendance 
at breast screening clinics throughout all demographic groups. This can also be 
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reflected in more recent times with the development of the disease in celebrities. Their 
impact today perhaps, is not as significant given the increased general awareness of 
the subject. 
Endocrine factors 
There are a number of endocrine factors that are said to have a proven causal link and 
others that have less well established influences. Known positive influences towards 
the development of breast cancer include an age at menarche < 12 years and an age at 
menopause > 55 years, which are said to have a relative risk of 1.3 and 1.5-2 
respectively [16]. The early onset of menstrual cycles, late menopause, delayed 
childbearing and a lower cumulative period of lactation reflect a prolonged exposure 
to endogenous oestrogens and render women with an increased propensity towards 
the development of breast cancer. Several reports have cited the protection from 
breast cancer afforded by prolonged breast-feeding. However, it has been suggested 
that racial differences in endocrine function do not explain the geographical variation 
in disease prevalence and a direct causal link will only be established with risk factor 
standardised studies [17]. 
Less well established influences in the causation of breast cancer include hormone 
replacement therapy (HRT) and the oral contraceptive pill. Data on HRT is 
conflicting but overall consensus appears to be that a short duration < 5 years 
appeared to be safe whereas a duration > 5 years was associated with a relative risk of 
> 1.4 [18]. The oral contraceptive pill is not reported to have an increased risk for 
breast cancer by numerous authors, but there is controversy here as well. A large 
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review of 54 epidemiological studies published in the Lancet in 1996 including 
150,000 women has shown a very small increase, but an increase nonetheless of 0.05 
excess cases per 100,000 women aged 16-19 years and 0.47 excess cases per 100,000 
women aged 25-29 on the pill. It is interesting in this context, that these tumours were 
found to be less advanced [19]. 
1.2 TUMOUR MARKERS 
In order to assist the surgical management of breast cancer patients, it has become 
common practice to perform serum and/or immunohistochemica1 testing for tumour 
markers. These may include steroid hormone receptors, CEA, epithelial mucins (e.g. 
CA15.3), tumour suppressor genes (e.g. p.53, retinoblastoma gene), oncogenes (e.g. c-
myc, c-erb B2(HER2), ras), proteases (e.g. cathepsin D), growth factor receptors (e.g. 
EGFR), proliferation markers (e.g. Ki-67), adhesion molecules (e.g. E-cadherin, 
integrins) and tumour DNA ploidy and S phase fraction [20]. A detailed discussion of 
these is beyond the scope of this thesis and only the salient features of proteinaceous 
markers that are clinically relevant are mentioned below. 
1.2.1 Serum tumour markers 
These include CEA and epithelial mucins (e.g. CA15.3). CEA is a family of high 
molecular weight glycoproteins produced in embryonic tissues of the gastrointestinal 
tract and its level is seen to be raised in between 25-50% of breast cancers. However, 
their levels can also be seen to be raised in a variety of conditions including hepatitis, 
inflammatory bowel disease, pancreatitis, chronic lung disease and even smoking. 
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The epithelial muc ins are members of the MUG-/ gene family, and these along with 
CEA have not been found to be useful for diagnostic purposes as their sensitivity is 
low (15-35% in early breast cancer) [21]. However, serum levels of these have been 
found to be related to tumour stage with significantly higher values obtained from 
patients with nodal involvement than in those without and in patients with larger 
tumours. This would implicate the use of these as independent prognostic factors and 
several studies have shown a shorter disease free survival and overall survival with 
rising levels, but others report conflicting data. Their main use appears to be in the 
monitoring of treatment and follow up for those with distant metastases and used in 
combination, their sensitivity increased to 95%, with patients responding to treatment 
showing decreasing levels of these markers [21]. 
1.2.2 Tissue tumour markers 
Steroid hormone receptors 
Steroid receptors are currently the only markers accepted in standard clinical practice, 
with immunohistochemistry for them being performed routinely as part of the 
histological diagnosis. Although, not useful in diagnosis, they have prognostic value 
in primary and metastatic breast cancer. The progesterone receptor is the product of a 
gene located on chromosome 11 and though its presence or absence in breast cancer is 
important, it appears to have less impact on prognosis. 
In 1958, Elwood Jensen showed that by using a radioactive marker, only tissues that 
were able to respond to oestrogen, such as those of the female reproductive tract were 
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able to concentrate it when it was injected in their blood. By 1968, he had devised a 
test that could detect the presence of oestrogen receptors on breast cancer cells. Since 
then, Szego and Pietras in the 70's have identified the membrane bound oestrogen 
receptor which when activated by oestradiol, increased intracellular second messenger 
cAMP levels. This appears to be produced by a gene complex located on chromosome 
14. Steroid hormone receptor positive status has been considered favourable for some 
time now and subsequent to its identification has become the most significant 
prognostic marker for breast cancer. Only recently, a second isoform of OR termed 
ORfi was discovered in 1996 [22] and the two isoforms exhibit different tissue 
distribution and overlapping but distinct actions. This has been validated by OR 
knockout studies in mice [23]. 
OR is a member of a large family of nuclear receptor transcription factors with 
characteristic structural domains. The two isoforms share 47% of their sequence 
identity with heterologous N-terminus transactivation domains (AF-1) and conserved 
DNA- and ligand-binding domains [24]. Hormone binding to the C-terminus ligand-
binding domain induces a receptor dimerization and conformational change that 
triggers the stimulation or inhibition of genes. The exact mechanism of OR induced 
gene transcription is still poorly understood. 
It has been stated that the # unit of OR is an important modulator of proliferation and 
invasion of breast cancer cells and loss of its expression may predispose to cancerous 
change [25]. Indeed, Palmieri et al have shown that ORfi variants and not ORa are 
expressed in human adult mammary fibroblasts. These results reveal that the 
proliferative signals derived from adult breast tissue in response to oestrogen are not 
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mediated by ORa as is currently thought [26]. Although it shall be some time yet 
before this controversy is clarified, proteomic sciences may help in elucidating this 
further. 
The next step in the evolution of what we know about the oestrogen receptor led to its 
being used as a target for modulation in the treatment of breast cancer and other 
diseases in which it was involved. An anti-oestrogen drug, Tamoxifen was developed 
in 1962 for use as the morning after pill, although its precise mechanism of action is 
still unknown. A decade later its use in the treatment of breast cancer began to be 
investigated and it has now been the mainstay of hormonal therapy in breast cancer 
for the last 25 years. In relation to this, the Early Breast Cancer Trialists' Group had 
conclusively showed the improved 10 year survival for patients with early breast 
cancer (resectable) treated with adjuvant Tamoxifen [27]. Since then, further trials 
(Breast Cancer Prevention Trial) have been conducted by the NCI (National Cancer 
Institute, USA) and concluded in 1998 have shown that high risk women, when 
treated with Tamoxifen, reduced their chances of contracting the disease by 44% [28]. 
Sequence data for ORa has been listed on the ExPASy (Expert Protein Analysis 
System) server of the Swiss Institute of Bioinformatics (with corresponding mirror 
sites at the Australian Proteome Analysis Facility, Sydney and six other nations 
around the world) as a UniProtKB/Swiss-Prot entry since 1986 (ESRl_HUMAN, 
primary accession number P03372) and is made up of 595 amino acids with a 
molecular weight of 66.216kDa (http://au.expasy.org/uniprot/P03372) . In addition, all 
eight described isoforms of OR/3 have also been listed on the same server as 
UniProtKB/Swiss-Prot entries (ESR2_HUMAN, primary accession number Q92731) 
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since 1999, the prototype of these 00- 1 is made up of 530 amino acids with a 
molecular weight of 59.216kDa (htt 	roU 92731). Similarly, the 
progesterone receptor has its own corresponding UniProtKB/Swiss-Prot entry 
(PRGR_HUMAN, primary accession number P06401) since 1988, being defined in 
two isoforms A and B, consisting of 933 amino acids and a molecular weight of 
98.995kDa (http://au.expasy.org/uniprot/P06401).  
Proteases 
Cathepsin D is a lysosomal aspartyl protease that can be rapidly assayed by 
conventional immunohistochemical techniques although routine use of this as a 
marker has not been supported due to the lack of significant data from multivariate 
analysis. However some authors have displayed strong associations between stromal 
Cathepsin D expression and high tumour tumour grade (p=0.003), increased tendency 
to local recurrence (p=0.009), regional recurrence (p=0.006), poorer disease free 
survival (p=0.0001) and poorer overall patient survival (p=0.0086) [29, 30]. Results 
are thus conflicting and results of further research are awaited. Cathepsin D has been 
listed on the ExPASy server as a UniProt/TrEMBLE entry since 2004 (CTSD protein, 
lysosomal aspartyl protease, Q61B57_HUMAN, primary accession number Q61B57) 
and is made up of 412 amino acids with a molecular weight of 44.552kDa 
(http://au.expasy.org/uniprot1061B57).  
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Growth factor receptors 
EGFR or Human Epidermal Growth Factor Receptor (HER) is part of the tyrosine 
kinase superfamily of receptors and has been shown to play an important role in the 
development of the normal breast as well as the progression into breast cancer. It has 
been found to be present in four isoforms (HER1-4). Recent evidence suggests that 
HER1-3 are associated with a poor prognosis, whereas HER-4 may be associated with 
good prognosis tumours [31]. 
Of these, HER-2 is the most clinically relevant and is a 185kDa cell surface receptor, 
discovered in the 1970's which is a product of the HER-2 or c-erbB2 proto-oncogene 
and in the 1980's was shown by Slamon et al to be linked to breast cancer as an 
independent prognostic marker, associated with more aggressive tumours [32] [33]. 
HER-2 alone has no known ligand, but forms heterodimers with HER-1 (EGFR), 
HER-3 and HER-4. This results in the activated receptor transmitting growth signals 
to the nucleus. Overexpression of this glycoprotein has been found to be associated 
with invasiveness, a lack of response to standard chemotherapy and is seen in up to 
25% of breast cancers [34]. This can be correlated with several negative prognostic 
variables including OR negative status, high S-phase fraction, positive nodal disease, 
mutated p.53 and high nuclear grade. 
HER-2 can be rapidly assayed using conventional immunohistochemical means 
(HercepTest), FISH (Fluorescent in situ hybridization, PathVysion) and CISH 
(Chromogenic in situ hybridization, Invitrogen). Immunohistochemical testing for this 
has now become routine in the assessment of breast cancer. 
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In parallel with the development in oestrogen receptor modulation, a recently 
developed monoclonal antibody to the HER-2 receptor protein, Herceptin 
(Trastuzumab) is now available in some countries. Its mechanism of action is 
synergistic with chemotherapeutic agents and Tamoxifen [35], HER-2 receptor down-
regulation, limiting the signal for further growth [36] and the potentiation of antibody 
mediated cellular cytotoxicity (ADCC) by facilitating the interaction between NK 
(Natural Killer) cells and HER-2 receptor/antibody complex causing lysis [37]. The 
landmark multicentric, randomized, controlled clinical Herceptin trial was published 
in 2001 encompassing 469 patients. In this report, Slamon et al reported that patients 
randomized to receive Herceptin and chemotherapy, versus those that received 
chemotherapy alone, showed a significantly longer median time to disease 
progression, higher overall response rate, longer median duration of response and 
longer median survival [38]. This protein has been listed on the ExPASy server as a 
UniProtKB/Swiss-Prot entry since 1987 (Receptor tyrosine protein kinase erbB-2, 
ERBB2_HUMAN, primary accession number PO4626) 
(http://au.expasy.org/uniprot/PO4626). 
Proliferation markers 
The expression of the human Ki-67 protein has been found to be a marker of cellular 
proliferation as, being present in the nucleus, it is relocated to the chromosomal 
surface during mitosis and is present in all active phases of the cell cycle barring GO 
(resting phase). The growth fraction of a tumour is represented by the Ki-67 labelling 
index and this has been found to correlate with survival and tumour recurrence based 
on uni- and multivariate analyses. It does not appear however, to be related to tumour 
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metastases [39]. Pietilanen et al have shown by multivariate analysis in axillary node 
negative cases that tumour size and Ki-67 labelling were independent prognostic 
factors [40]. The Ki-67 molecule is a large 359kDa ubiquitous nuclear protein made 
of 3256 amino acids. It has been listed on the ExPASy server as a UniProtKB/Swiss-
Prot entry since 1995 (Antigen KI-67, KI67_HUMAN, primary accession number 
P46013) (http://au.expasy.org/uniprot/P46013).  
1.3 INTRODUCTION TO PROTEOMIC SCIENCES 
All cells, eukaryotic or prokaryotic are made of a conglomeration of heterogeneous 
molecules, namely lipids, polysaccharides, proteins, nucleic acids, minerals and 
water. There can be no question as to the significance of DNA in the carriage of 
genetic code that allows propagation of the species. However, it has been at times 
quite difficult to link gene sequence data to the onset of disease. This disparity 
between the two is filled by secondary messengers and effector molecules such as 
RNA and proteins. 
We know that the synthesis of effector molecules progresses through the transcription 
of a DNA template into mRNA and its subsequent translation to protein. The study of 
mRNA has arisen as a means of studying the translation of genetic code and certainly 
numerous studies have been performed with this idea in mind [41]. It is however, 
important to appreciate that while mRNA based approaches measure message 
abundance they do not measure the actual effector molecules, the proteins, 
themselves. A protein cannot be synthesized without its mRNA template, but there 
can be an abundance of protein in a cell when its mRNA is sparse and conversely, 
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there can be an abundance of mRNA in a cell and no protein synthesis. In addition, 
once a particular protein is synthesized from a single strand of mRNA, it can be 
spliced, truncated at its C- or N-termini or various substituent groups added. Hence, a 
particular protein can be post-translationally altered in numerous ways. These facts 
give rise to the analogy as stated by Wilkins, MR et al that the protein make-up of a 
cell at a particular time varies with its state of development, the pH and the 
environmental conditions. A hepatocyte for example, may have a drastically different 
protein make-up after as little as a glass of wine [42]. 
It was not until the 1970's that the separation of proteins was found to be possible in 
two dimensions. One of the first published reports of this technique by Kenrick KG et 
al, combined native Iso-electric focusing (IEF) with pore gradient SDS-PAGE 
(Sodium Dodecyl Sulphate — Polyacrylamide Gel electrophoresis) to separate serum 
proteins [43]. There was, however, a handicap in the form of a lack of capability in 
data analysis. With the development of information technology and specifically `bio-
informatics', software was developed that enabled the analysis of large amounts of 
experimental data. With this came the advent of proteomics, when, at the Siena 2D 
Electrophoresis meeting in late 1994, two Australian Scientists, Keith Williams and 
Marc Wilkins coined the word "proteome", denoting a set of PROTEins encoded by 
the genOME [42]. Indeed, the rise in popularity of proteomics as a science could be 
said to mirror software development. 
With the mapping of the human genome, emphasis has been placed on the search for 
loci of cancer development. There have been numerous reports of identification of 
regions of loss of heterozygosity (LOH) and their implication in the pathogenesis of 
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breast cancer with the aid of the human genome[44-48]. In addition, Osborne et al 
have integrated data from 143 studies on allelic imbalance, including identification of 
BRCA1 and 2 loci as well 24 other regions on 16 chromosomes [44]. Other 
researchers have utilized genomic studies to display linkage analyses in 14 Finnish 
breast cancer families that did not display germline mutations in BRCA1 and 2 genes. 
Of most interest was region 2q32 and this would certainly warrant further study [49]. 
There is thus, a great potential for further progress. 
The fields of genomics and proteomics are not necessarily conflicting but rather 
complementary, as mentioned above, proteins are the effector molecules of normal or 
disordered genetic loci. In other words, the proteomic profile of breast cancer is a 
reflection of the genetic make up of the tumour. However, proteins being effector 
molecules, are a potential target for modulation, implying that a disordered gene is 
already manifest. This has clinical implications for the treatment of breast cancer 
rather than prophylaxis. This conceptual difference was one of the main 
considerations behind the choice of proteomic study. 
1.4 TWO DIMENSION GEL ELECTROPHORESIS 
The human breast is a highly specialized, complex and tenacious tissue, consisting of 
a heterogeneous population of cells with varying function. Sample acquisition for the 
purpose of proteomic analyses generally requires bulk tissue collection. For general 
use purposes this may be adequate. In highly specialized laboratories, however, the 
advent of laser capture microdissection (LCM) techniques whereby a focused laser 
beam targets specific groups of cells, holds promise for the future. Retrieval of the 
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concerned group of cells is conducted by the concomitant activation of a transfer film 
placed adjacent to the tissue section [50]. 
A Medline search conducted in the year 2001 revealed little in the way of breast tissue 
sample preparation. However, there is evidence of the quality of sample preparation 
being the determinant of a reliable measurement of protein expression in patient cells 
or tissue biopsies [51]. As a product of the work of Franzen in the early 90's, 
guidelines are available for the preparation of tissue biopsies. Yet, information on the 
preparation of intact breast cancer/ normal breast tissue specifically is limited. 
Various publications exist on the application of 2D gel electrophoresis towards the 
separation of polypeptides amongst cultured human breast cell lines, the majority 
involving the use of MCF7 (oestrogen receptor positive) and MDA-MB231 
(oestrogen receptor negative) and other less well described lines such as Hs578t, 
ZR75-1 and MB468. However, as highlighted by Giometti eta!, these approaches 
failed to demonstrate the differences in terms of gene expression, between these lines 
and the tumours in situ [52]. 
The preparation of intact tissue samples has progressed greatly over the years. In the 
early years, solubilization consisted of a single stage extraction. It was only later that 
sequential extraction parameters evolved to aid in the separation of cytosolic, 
membrane and microsomal fractions. Weiss et al described a sequential extraction 
protocol for the separation of barley seed proteins in 1992 [53]. Molloy MP et al 
have spoken about the identification of membrane proteins in E.coli whole cell lysates 
using this method that were previously thought to be open reading frames [54]. 
Various biomedical laboratories have since formulated reagents that are available in 
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an easy to use 'kit' form along with E.coli whole cell lysates as a training tool. This 
has greatly facilitated the adequate preparation of samples. 
The presence of nucleic acids has a detrimental effect on protein separation. DNA 
complexes dissociate under the denaturing conditions of sample preparation. This 
inhibits protein entry and migration into the gel. In addition, DNA binds to proteins 
and leads to artefact and streaking in gels. In 1986, Rabilloud described performing 
the extraction at high pH, at which proteins behave as anions and complex formation 
with anionic nucleic acids is minimized [55]. However, addition of endonuclease to 
the sample after solubilization has been found to be satisfactory and can be performed 
as a single step. 
Despite the sensitivity of currently available technology including infra-red matrix 
assisted laser desorption ionisation mass spectrometry (1R-MALDI-MS), analysis of 
low abundance proteins remains challenging [42] and traditional biochemical 
techniques are employed to help visualize minor proteins and reduce protein sample 
complexity such as differential extraction [54], subcellular fractionation [56] and 
hydroxy-apatite chromatography [57]. The separation of basic proteins such as 
ribosomal and nuclear proteins had also long been held problematical and the system 
most widely used for the lEF of these proteins was non-equilibrium pH gradient 
electrophoresis (NEPHGE) and its attendant problems. A detailed description of these 
techniques is beyond the scope of this thesis. The advent of 'zoom in' 1PG gel strips 
however, specifically over the alkaline range has been a major development in the 
resolution of basic proteins into highly reproducible 2D patterns [58]. 
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Sample loading can be performed by various means and each has had its advocates. 
Traditional methods involve cup loading and in-gel re-hydration of Immobilized pH 
Gradient strips (IPG). Some authors also describe a paper-bridge loading method [59]. 
These have been reported to allow the application of a much larger protein load and 
an improved spot resolution. In addition, 2D gel electrophoresis techniques have 
become simplified of late by integrated systems where in-gel re-hydration and iso-
electric focusing can be conducted as a simple, one step overnight procedure. 
Immobilized pH gradient (IPG) strips were developed for the ease of predicting the 
position of unknown bands against proteins whose amino acid structure and iso-
electric point (pI) were known. This approach had been experimentally verified by the 
work of Bjellqvist B et al [60]. Salt and buffer ions in the sample as well as in IPG 
strips can interact with the protein load and determine the ultimate resolution in the 
first dimension. Current practice dictates the application of sample along the entire 
length of the IPG strip. There have been reports by Strahler JR et al in 1988, however 
of more efficient sample entry occurring by its application at the anode end for 
samples re-hydrated in 1-2mM Tris base and at the cathode end for samples re-
hydrated in 1-2mM Acetic acid [61]. This avoided in addition, the phenomenon of 
lateral band spread and increased spot resolution in the first dimension. This 
explanation is not tenable today, as the above description was applicable to the older 
tube gel systems that are being phased out in favour of IPG strips for ease of 
reproducibility. Current commercially available IPG strips are retailed in a dehydrated 
form (Bio-Rad). 
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Reducing agents such as Tributylphosphine (TBP) and Dithiothreitol (DTT) improve 
protein solubility by their action on disulfide bonds. Proteins cannot be viewed as 
independent units without bond disruption. DTT is a thiol reducing agent that forces 
equilibrium towards reduced cysteine groups and to a certain extent minimizes 
oxidation from the atmosphere. TBP is non-charged and hence, some authors believe 
that the use of TBP in place of DTT results in increased protein solubility and 
increased transfer to the second dimension [62]. However, as noted by Altland K et al 
in 1988, even in the presence of these strong reducing agents, polyacrylamide gels 
function as electron acceptors for sulfhydryl groups in proteins [63]. 
In order to achieve reproducibility between first dimension runs and permit full-scale 
proteome analysis, it is vital to maintain a set group of parameters. There are a 
number of variables that come into play, including total sample amount, voltage and 
time parameters. The temperature at which iso-electric focusing takes place also needs 
to be taken into account. Gorg et al described, in a landmark article published in 1991, 
the effects of temperature on spot position and pattern quality. Increased temperatures 
were found to reveal altered 2D images in terms of sample entry, resolution and 
background staining. First dimension separation at 20° C was found to be superior 
compared to 10 or 15 ° C in terms of resolution. At 30 ° C however, spots were 
discovered to have migrated, as evident on computer based analysis. Given this, they 
would have been even more surprised to find that the direction in which the spots 
migrated was not constant for all [64]. 
It has been said that broad range IPG strips are used for analysis of simple prokaryotic 
proteomes. It is clear though, that to enable the detailed analysis of more complex 
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eukaryotic organisms and tissues, a greater degree of focus is required. With this in 
mind, narrow range and very narrow range (gradient 3.5-4.5, 4-5, etc.) `zoom-in' IPG 
strips have been developed. Mass spectrometry has identified the superior ability of 
very narrow range IPG strips to separate different proteins species and isoforms 
compared with broader range strips [65]. 
Following the second dimension separation on a polyacrylamide gel, visualization is 
undertaken by means of numerous staining techniques. In the context of proteomics, 
the most suitable stain available is silver and various commercially available 'kits' are 
available along with their protocols [66]. Spots containing between 10-100nanograms 
of protein can be easily detected and gels do not require specialized image acquisition 
tools. In addition, excised spots can be subjected to mass spectrometric analysis 
(although standard silver stain is not compatible with this, as an additional oxidative 
step in the process changes protein mass) [67]. In specialized laboratories however, 
SYPRO fluorescent stains are preferred for an even greater sensitivity 
(<10nanograms), although specialized and costly image acquisition tools are required 
for gel analysis. Lopez MF et al have reported the advantages of fluorescent stains 
over silver in detail and include a broader dynamic range and enhanced recovery of 
peptides from in-gel digests for the purpose of matrix assisted laser desorption 
ionisation time of flight (MALDI-TOF) spectrometry [68]. As reported by the work of 
Lauber WM et al this phenomenon also correlates with the number of protein 
database matches and percent sequence coverage [69]. 
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1.5 PROTEIN IDENTIFICATION AND PROTEOME DATABASES 
In the early years of 2D gel electrophoresis, although protein sequencing had been 
defined and automated [70], much data in gels was relegated to spot description and 
classification, as software capable of handling such data was not yet developed. 
Today however, advances in proteomic technology and software enable the precise 
protein spot identification on 2D gels. The aim of any proteome study is to allow the 
accurate identification of proteins preferentially expressed in a given tissue and newer 
third generation software packages such as Melanie 4 (Geneva Bioinformatics), 
ImageMaster 2D Platinum 5.0 (Amersham Biosciences) and PDQuest version 7.0 
(Bio-Rad) have been developed to aid in this regard. The ultimate responsibility 
however, lies with the 'human' researcher being able to identify the protein spots of 
interest. 
Spots of interest once identified need to be isolated. The Bio-Rad Corporation and 
others have developed automated spot excision tools (e.g. the Proteome Works spot 
cutter from Bio-Rad). This tool is integrated with PDQuest and allows precise 
localization of a particular spot of interest on a gel and concomitant isolation of spot 
containing gel material. Using such an approach, the working time, is claimed to be 
reduced by 50% with a corresponding reduction in errors [67]. 
The further characterization of proteome data can be performed by means of a peptide 
mass fingerprint obtained through matrix assisted laser desorption ionisation — time of 
flight (MALDI-TOF) mass spectrometry, liquid chromatography-tandem mass 
spectrometry [69], nano-electrospray ionisation mass spectrometry (ESI-MS) [71], or 
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by means of amino acid sequence analysis from blotted membranes subjected to 
automated Edman degradation [72]. These indirect and direct methods of protein 
sequencing are too complex to be discussed at any great length in the current context. 
In addition to the above sophisticated techniques, there are simpler methods available 
for the characterization and identification of proteome data, though not necessarily as 
accurate. The matching of proteins can be performed with theoretical pI and 
molecular weight data (computed with the use of experimental standards) against 
those of known proteins in proteome databases such as SWISS-Prot/TrEMBL, 
PUMA, Prosite, and SWISS-2DPAGE. SWISS-Prot also allows cross-species 
matching against all proteins from a chosen genus, family, phylum or kingdom [42]. 
However, it needs to be mentioned that though SWISS-Prot contains a large number 
of entries, they are mainly from 30 or so species on which a protein sequence focus 
has been maintained. Clearly, this is not very accurate and mainly serves as a means 
of exclusion of other proteins. In relation to this, human breast proteome databases 
have been posted on the world wide web (http://proteomeweb.anl.gov/)  since 1995 by 
the Argonne National Laboratory, Illinois [52], as well as at the Siena 2DPAGE 
database for malignant and normal breast proteins (http://www.bio-
mol.unisi.it/2d12d.htm) . This will facilitate the identification of preferentially 
expressed polypeptides in breast cancer as well as generate interest in this 
subspecialty of proteomic investigation. 
Our understanding of the pathogenesis of breast cancer has developed over the years 
along with the list of genetic and environmental factors involved. To this regard, there 
have been key scientific developments that have translated into a clinical application. 
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The oestrogen and her-2 receptors are prototypes that have led to therapy being 
developed to modulate their response. The differences displayed by these factors in 
varied population groups however, have not been addressed to date. This is the 
rationale behind our experiments. 
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2.0 MATERIAL AND METHODS 
2.1 SAMPLE ACQUISITION AND ETHICS APPROVAL 
1. Ethics approval 
This was obtained from the Royal Hobart Hospital Ethics committee (project no. 
2001.02) with the submission of a patient information sheet and consent form. A 
copy of the mentioned documents is included in this thesis. Similar arrangements 
were made for ethical approval from the Hobart Private Hospital and the Calvary 
Hospital. 
2. Patient recruitment and sample acquisition 
Surgeons performing the relevant surgery were contacted and their consent 
obtained for access to patients in the public hospital as well as the private sector. 
Patients themselves were subsequently approached and interviewed with regard to 
a clinical history including current medications, hormone replacement, previous 
treatment received and family history. Data was recorded in tabular form (Table 
11, pg 72). This session included a discussion of consent issues and was most 
conveniently performed in a preadmission clinic setting, 1-2 weeks prior to the 
date of surgery. A potential complicating factor in sample procurement was the 
requirement for fresh breast and nodal tissue rather than tissue fixed in formalin. 
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Due to this, special arrangements were made with Hobart Pathology, CentrePath 
(private pathology diagnostics) and the Anatomical Pathology department at the 
Royal Hobart Hospital. This included the direct collection of suitable specimens 
by the author at the site and time of excision, to be transported to the relevant 
anatomical pathology laboratory where tissue was obtained if deemed feasible. 
Nodal tissue samples deemed suitable for collection were bisected and half of the 
node was retained by the relevant pathology lab for histological confirmation. 
Subsequently, the breast tissue specimen was fixed in formalin and the tissue 
sample for the purpose of proteomic investigation was transported to the surgical 
laboratory and stored at —70°C in an appropriately sized container without any 
required preparation. 
2.2 SAMPLE PREPARATION FOR PROTEOME ANALYSIS 
The following tables list the disposable goods, hardware and reagents used in sample 
preparation. 
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Instrument Manufacturer/Distributor 
Scalpel handle no.4 Bard-Parker (U.S.A.) 
Sterile surgical blade no.25 Swann-Morton (England) 
Airpure biological safety cabinet class II Email Westinghouse 
Disposable plastic petri dish Disposable Products Pty Ltd (Australia) 
Plastic weighing boats (cat no. W3001) Sigma-Aldrich 
Non-sterile gloves (powder free) Anse11 
Weighing machine (SC2020) Ohaus (U.S.A.) 
Pyrex 2m1 homogenizer (cat no. 7727-02) Crown-Scientific Pty Ltd 
Ultra-Turrax 18 electric homogenizer Inka Labortechnik 
Gilson pipetman (20,200,1000microlitre) John Morris Scientific 
Tips pipetter, polypropylene 
(200,1000microlitre) 
Sorenson 
Micro test tubes 1.5m1 Eppendorf 
Centrifuge 5415D Eppendorf 
Plastic test tube rack Nalgene 
Freezer F230 Fisher-Paykel 
Refrigerator C270 Fisher-Paykel 
Polystyrene 96 well cell, flat bottom Corning 
Microplate reader model 3550 Bio-Rad 
Duran Jena-glas laboratory bottles 100m1 Schott-Mainz 
Protean lEF system, including basic unit, 
11 cm focusing trays with lids, 2 pairs of 
stainless steel forceps, pack of electrode 
wicks, mineral oil and cleaning brush (cat 
no. 165-4000) 
Bio-Rad 
Electrode wicks pre-cut (cat no. 165-4071) Bio-Rad 
Disposable re-hydration/equilibration tray 
11cm (cat no. 165-4025) 
Bio-Rad 
ReadyStrip IPG strip, 11cm, pH 3-10 (cat 
no. 163-2014) 
Bio-Rad 
Criterion precast Tris-HC1 gel, 4-15% (cat 
no. 345-0031) 
Bio-Rad 
Criterion 2D cell (cat no. 165-6001) Bio-Rad 
GS-800 Calibrated Imaging Densitometer, 
PC (cat no. 170-7980) 
Bio-Rad 
PDQuest 2-D Image Analysis Software, PC 
(cat no. 170-8603) 
Bio-Rad 
Table 1: Disposable goods and Hardware in 'Analysis of the breast cancer proteome'. 
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Reagent/Chemical Catalogue no. Manufacturer 
ReadyPrep Sequential Extraction Kit, includes 1 vial 
of reagent 1 (to make 50 ml), 2 vials of reagent 2 (to 
make 10 ml each), 2 vials of reagent  3 (to make 10 ml 
each), 1 vial containing 0.6 ml of 200mM TBP 
163-2100 Bio-Rad 
Protease inhibitor cocktail P-8340 Sigma 
TRIZMA base T-1503 Sigma 
Urea 161-0731 Bio-Rad 
CHAPS 161-0460 Bio-Rad 
Bio-Lyte 3/10 Ampholyte 163-1112 Bio-Rad 
Thiourea 24025-7 Aldrich 
Caprylyl sulfo-betaine SB3-10 D4266 Sigma 
Tri-butyl phosphine (TBP) 163-2101 Bio-Rad 
Protein assay dye concentrate 500-0006 Bio-Rad 
Protein assay standard (bovine gamma globulin) 500-0005 Bio-Rad 
Deoxyribonuclease D-0876 Sigma 
Iso-electric focus (IEF) standard 161-0310 Bio-Rad 
Bromophenol blue B-8026 Sigma 
Mineral Oil 163-2129 Bio-Rad 
Sodium dodecyl sulphate (SDS) 161-0301 Bio-Rad 
Glycerol G-7893 Sigma 
Dithiothreitol (DTT) 161-0611 Bio-Rad 
Iodoacetamide 163-2109 Bio-Rad 
Glycine G-7126 Sigma 
Precision protein molecular weight standards 161-0372 Bio-Rad 
Low Melting Point (LMP) overlay agarose 162-0019 Bio-Rad 
Fixative enhancer concentrate 161-0461 Bio-Rad 
Methanol 10158.6B BDH 
Acetic acid 100015N BDH 
Coomassie brilliant blue R-250 161-0400 Bio-Rad 
Silver Stain Plus Kit 161-0449 Bio-Rad 
Silver Complex Solution 161-0462 Bio-Rad 
Reduction Moderator Solution 161-0463 Bio-Rad 
Image Development Reagent 161-0464 Bio-Rad 
Development Accelerator Concentrate 161-0448 Bio-Rad 
Sodium Azide 30111 BDH 
Table 2: Reagents and chemicals used in 'Analysis of the breast cancer proteome'. 
Sample preparation required the thawing of earlier obtained breast tissue. This was 
performed at room temperature. It was determined that samples weighing 100mg, 
obtained after the dissection of macroscopically evident fat tissue in a disposable 
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as, 
plastic petri dish would be adequate for the purpose of breast cancer proteome 
investigation. Factors such as amount of tumour tissue available, adequate 
centrifugation using appropriate Eppendorf vials and the isolation of a satisfactory 
number of gel spots were taken into account when coming to this conclusion. This 
was performed within a biological safety cabinet and any unused sample was returned 
to the —70°C refrigerator. 
Although a standardized sample weight was used, a modified Bradford protein assay 
was performed on randomly selected samples. Bradford dye concentrate (Bio-Rad) 
was used in a 1:5 dilution with bovine gamma globulin as control in a concentration 
of 1.43mg/m1 of de-ionized distilled water (milli-Q). 
Figure 6: Dissection of breast tissue. 
Sequential extraction was performed according to the protocol described by Bio-Rad 
Laboratories. 
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Figure 7: Flowchart for sequential extraction. 
Extraction 1 
• Homogenization step — To the tissue sample was added 20microlitres of 
protease inhibitor cocktail (mixture of protease inhibitors with broad 
specificity for inhibition of serine, cysteine, and aspartic proteases, and 
aminopeptidases) and 1 ml of sequential extraction reagent 1 (40mM Tris 
base). Homogenization was carried out manually in a hand held Pyrex 2m1 
homogenizer and aided by an electrical homogenizer. The contents were then 
transferred to a 1.5m1 micro test tube (Eppendorf). 
• Centrifugation step — The sample containing micro test tube was micro-
centrifuged (5415D, Eppendorf) using an appropriate counter balance at a rate 
of 13,200 rpm for a period of 15 mins. Supernatant was then extracted and 
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transferred to a new micro test tube, labelled Solution 1 (with appropriate 
identifying data and date of manufacture) and stored at —20 °C. The insoluble 
pellet was then extracted by forceps (swabbed with 70% ethanol) and 
transferred to the homogenizer for further processing. 
_ Extraction 2 
• Homogenization step — A 1:50 dilution (20microlitres) of reducing agent TBP 
in lml of sequential extraction Reagent 2 (Table 5, pg 68) was added to the 
insoluble pellet which was homogenized and transferred to a micro test tube. 
• Centrifugation step — This was performed at 13,200 rpm for 13 mins. The 
obtained supernatant was labelled Solution 2. 
Extraction 3 
• Homogenisation step — a 1:50 dilution (20microlitres) of TBP reducing agent 
in lml of sequential extraction Reagent 3 (Table 6, pg 68) was added to the 
insoluble pellet from extraction 2. The contents were then transferred to a 
micro test tube as described above. 
• Centrifugation step — performed as described above at 13,200 rpm for a period 
of 13 mins following which the supernatant was extracted, transferred to a 
new micro test tube and labelled Solution 3. The remaining insoluble pellet 
was discarded. 
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This protocol took into account the variable solubilization properties of the three 
reagents, with reagent 1 extracting hydrophilic cytosolic proteins and reagents 2 and 3 
extracting increasingly hydrophobic proteins. The resultant solutions at times showed 
increased viscosity, reflecting the presence of nucleic acids as was evident by the poor 
separation during the first dimension focus. These were then subjected to enzymatic 
digestion by the addition of endonuclease or placement in a warm water bath. This 
was found to be more of a concern during the preparation of nodal samples. The 
sample solutions were then stored in standard Eppendorf vials at —20°C pending 
further processing. 
2.3 SAMPLE LOADING 
Due to the presence of potentially interfering abundant cytosolic proteins, Solution 1 
was not processed further and only Solutions 2 and 3 were loaded on to IPG strips. To 
185microlitres of thawed sample solution was added a speck of bromophenol blue to 
provide colour contrast. 
Figure 8: Preparation of sample solution for re-hydration. 
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The solutions were then laid within the rows of plastic disposable re-hydration/ 
equilibration trays using standard micro-pipetting techniques. IPG strips of chosen pH 
gradient (3-10) and length (11cm) were then carefully placed on the solution taking 
great care to allow for even distribution and minimize the presence of air bubbles that 
could interfere with sample absorption. The rPG strips were then overlaid with 2m1 of 
mineral oil and left for overnight passive re-hydration. Even absorption of sample 
could be estimated by the presence of a uniform thickness throughout the Acrylamide 
gel layer of the IPG strips. 
A standard sample containing 15microlitres of IEF standard mixed with 
170microlitres of reagent 3 provided for pI estimation in the first dimension focus. 
This contained nine natural proteins with a pI ranging from 4.45-9.6. The IEF 
standard was similarly incubated onto an IPG strip that was re-hydrated overnight. 
2.4 FIRST DIMENSION SEPARATION 
An Iso-electric focusing (IEF) tray was suitably prepared by placing filter paper wicks 
over the electrode wires and moistened with 8microlitres of de-ionized water (milliQ). 
Re-hydrated IPG strips could now be subjected to a first dimension focus. Mineral oil 
was discarded from the re-hydration trays and IPG strips retrieved, placed in the 
focusing tray and overlaid with a further 2m1 of mineral oil per row. First dimension 
focusing then took place at room temperature (approximately 20 °C) according to the 
protocol set forth Bio-Rad for first dimension separation using the Protean IEF cell 
[67]. 
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Figure 9: Placement of electrode wicks. 
Figure 10: Placement of IPG strip in focusing tray. 
Figure 11: The Protean IEF cell (Bio-Rad). 
Step Voltage (v) Time (mins) Volt-hours Ramp 
1 250 20 Linear 
2 8000 150 Linear 
3 8000 20,000 Rapid 
Table 3: Set parameters for 11cm, pH gradient 3-10 IPG strips for the protean IEF  cell (Bio-
Rad). 
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Adequate focusing was ascertained by the gradual migration of bromophenol blue 
contrast to the opposing electrode. 
Figure 12: First dimension focus in progress. 
2.5 EQUILIBRATION OF IPG STRIPS 
In order to allow SDS binding in preparation for the second dimension separation, it 
was a pre-requisite to equilibrate focused IPG strips in SDS containing buffers. An 
equilibration base buffer was prepared according to the protocol set forth by Bio-Rad 
[67]. 
Equilibration took place in two steps. Firstly, according to Bio-Rad protocol (for 
11cm strips), 4m1 of buffer 1 (base buffer and Dithiothreitol to a concentration of 
2.5%, that reduces sulfhydryl groups) was placed in a disposable plastic re-hydration/ 
equilibration tray and incubated with gentle agitation for a period of 10min. This was 
followed by placement in 4m1 of buffer 2 (base buffer and dry Iodoacetamide to a 
concentration of 2.5% that alkylates sulfhydryl groups), and similarly incubated. 
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Following equilibration, the 1PG strips were embedded onto the second dimension 
gels as described. 
2.6 SECOND DIMENSION SEPARATION 
In order to provide savings in time and labour, as well as enable reproducibility, 
precision poured pre-cast gradient gels were utilized (Criterion 4-15% Tris-HC1, Bio-
Rad for 1 lcm IPG strips). In addition to equilibration, the transition from first 
dimension to second dimension focus involved the embedding of the 1PG strip in the 
well of a pre-cast gel cassette. The gel cassette was removed from its sealed plastic 
container and its well was washed gently in de-ionized water (milliQ). An appropriate 
Criterion second dimension focusing cell (Bio-Rad) was then filled to the set mark 
with tank buffer to be followed by the placement of gel cassettes in their respective 
trays. The 1PG strip was then carefully dipped in de-ionized water to rid it of excess 
buffer chemicals and air bubbles, placed in the cassette well and overlaid with low 
melting point Agarose (1% prepared solution in milliQ with bromophenol blue). 
Standard proteins were added to the gel in the form of an appropriately sized filter 
paper wick, containing 10microlitres of Precision Protein Molecular Weight 
Standards placed in the well beside the IPG strip. The stabilized 1PG strip then 
underwent second dimension separation once its well was further topped with tank 
buffer. 
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lut 
Figure 13: Criterion 2D focusing cell (Bio-Rad). 
Separation was performed according to Bio-Rad protocol at 200 volts for 65 mins 
[67]. The Migrating front was identified with the help of the constituent bromophenol 
blue. Following the completion of second dimension separation, gels were extracted 
by breaking open the containing cassette, marked for orientation and stored. Gel 
cassette trays are shipped, packaged in plastic containers that were utilized as vessels 
for gel storage. To the containers were added 100m1 of Fixative Enhancer Solution 
per gel followed by the gels themselves. These vessels were then placed in the 
refrigerator for overnight incubation. 
2.7 STAINING TECHNIQUES 
The silver stain plus kit (catalogue 161-0449, Bio-Rad) was utilized for gel staining as 
they were deemed to be sufficiently sensitive for our purpose. The components of the 
kit are as follows. 
• Fixative Enhancer Concentrate 
• Silver Complex Solution (containing NH4NO3 and AgNO3) 
• Reduction Moderator Solution (containing Tungstosilicic acid) 
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• Image Development Reagent (containing Formaldehyde) 
• Development Accelerator Reagent 
To enable the adequate staining of gels, the use of clean utensils and high quality de-
ionized distilled water was absolutely essential. Staining took place using the 
following steps. 
a. Preparation of Development Accelerator Solution 
950m1 of milliQ distilled water was placed in a 1L cylinder containing a Teflon stir 
bar. To the stirring water was added the entire 50g content of the Development 
Accelerator Reagent slowly. In order to adjust volume to 1 litre, further water could 
be added. Once fully dissolved, the solution was poured into the provided 1 litre bottle 
(provided in kit), labelled Development Accelerator Solution and stored at 4 °C. 
b. Rinse step 
The staining vessel was retrieved from the refrigerator and Fixative Enhancer 
Solution was decanted. 100m1 of milliQ water per gel was then added and the vessel 
gently agitated for a period of 10 mins. This cycle was repeated four times, decanting 
milliQ and replacing it with fresh milliQ after each cycle. 
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c. Stain step 
A staining solution was prepared to a volume of 100m1 per gel, to be used within a 
period of 5 minutes. A large beaker containing 35 ml milliQ water and a Teflon stir 
bar was placed on a stirrer. To this was added the following reagents in sequence, 
• 5m1 Silver Complex Solution 
• 5m1 Reduction Moderator Solution 
• 5m1 Image Development Reagent 
Immediately before use, 50m1 of room temperature Development Accelerator 
Solution was added to the beaker and stirred well. The contents of the beaker were 
then added to the staining vessel. Spots started to become Visible within 5mins and 
staining was dependant on the quality of sample prepared. The average time to 
adequate staining was approximately 15mins. 
d. Stop step 
A 5% Acetic Acid solution was prepared, to be used as a Stop solution. Staining 
solution was decanted once the gels were adequately stained and 100m1 of the Stop 
solution was added to the staining vessel. It was noted that a better result was obtained 
when gels were removed from the staining solution when slightly under-stained as the 
stop solution would increase spot definition and intensity. This was gently agitated for 
a further 15mins when stop solution was discarded and gels were ready for storage. 
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e. Storage step 
Having discarded the stop solution, gels were rinsed in 100m1 milliQ water for a 
further 5mins. This was then decanted and gels placed and sealed carefully in 
appropriately sized zip-lock clear plastic bags along with 2m1 of 5% Sodium Azide. 
The gels were now ready for image acquisition and long-term storage. However, in 
order to account for tumour heterogeneity as well as theoretical differences in the 
preparation of solutions, loading and running of gels on occasion, multiple gel images 
were created from selected samples (normal and cancerous) in order to confirm 
reproducibility. These individual images however were not differentially analysed or 
indeed kept on record. 
2.8 IMAGE ACQUISITION 
In order for 2D gels to be analysed with an image evaluation system they needed to be 
digitised. This was performed by way of Densitometry using the GS-800 calibrated 
imaging densitometer. 
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Figure 14: The GS-800 Calibrated Imaging Densitometer (Bio-Rad). 
The GS-800 densitometer is integrated with PDQuest software (Bio-Rad), a 
programme that enables analysis of 2D gels. On the File menu of PDQuest, the GS-
800 densitometer option was selected. The acquisition window of the densitometer 
was thus opened, displaying a control panel and a scanning window. The four basic 
steps to acquiring an image were then undertaken. 
1. Selecting the application (gel) 
2. Selecting the scan area by way of a preview scan. Using this as a guide the 
scan area was selected by dragging the mouse within the scan window. The 
border of the scan area was then marked with a frame. 
3. Selecting the scan resolution. This was performed by the select scan resolution 
dialog box. For the purposes of this study a medium resolution (63.5 x X 63.5 ), 
microns) was used as the default value. 
4. Image acquisition. Once calibrated the densitometer could acquire images by 
selecting the acquire image button. As the scan was completed the image 
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opened with a default file name, date and usemame and automatically saved as 
such once enabled. 
Figure 15: The GS-800 Calibrated Imaging Densitometer image acquisition sub-window. 
2.9 IMAGE EDITING 
This entailed the transformation of an image, adjusting brightness and contrast in 
order to optimise image display and did not alter the underlying data. Selecting 
Transform from the image menu opened a dialog box showing a smaller preview pane 
of the image to be transformed. Any changes were only reflected in the preview pane. 
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Figure 16: The Transform image dialog box. 
Using the high/low and gamma (non-linear) sliders the image was optimised 
manually. The log checkbox enabled an easier discernment of subtle changes in signal 
intensity and better distinguish peaks. Once satisfactory, the transform key was 
activated and the new image appeared in a window labelled as version 2. 
It was a pre-requisite when matching spots that all the Matchset images are of the 
same size and shape. In order for this to proceed, all images were cropped using the 
crop commands on the Image menu. Crop parameters were established using defined 
crop settings in terms of size. Accuracy of the crop was aided by the placement of a 
cross-hair on a landmark. Once the crop settings were selected, the cropped image 
appeared in a new window labelled as version 3. 
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Figure 17: Placement of established crop parameters following acquisition and transformation of 
gel images. 
2.10 SPOT DETECTION 
The spot detection wizard from the spots menu on the PDQuest interface  was used to 
select parameters for detecting spots in the gel scans. 
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Figure 18: PDQuest spot detection Wizard. 
The wizard requests manual guidance by marking features on the gel scan that were 
used to automatically select correct detection parameters, such as a faint spot, smallest 
spot, large spot and a large representative section of the gel image as background. The 
sensitivity of detection could be adjusted by changing the above-mentioned 
parameters. Test settings enabled the display of spots detected in the wizard window. 
In addition optional controls could be adjusted to remove gel streaking and 
background. 
However, in most instances, in order to avoid the indiscriminate detection of artefact 
as spots, a minimum sensitivity was utilized for spot detection using the wizard 
interface. The gel was then scanned manually by scrolling through the image and 
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spots added or removed using the edit spot tool. This method though somewhat 
laborious was found to be more accurate in terms of spot detection. Legitimate protein 
spots presented themselves as regular, round to ovoid entities, often in chains or 
clusters that could be easily differentiated from linear, irregular entities that were 
artefact. 
Once spot detection was_complete, PDQuest filtered the original gel-scan containing 
the defined number of spots and created a synthetic image containing the spots 
displayed as Gaussian intensity distributions. There are thus four images per gel, the 
original 2D gel scan, a cropped version of the scan, a filtered version and a synthetic 
Gaussian image. These images are all part of the same scan set and share the same 
root file name. 
2.11 MATCHSETS 
In order to compare spots across a large number of gels, a Matchset was created. This 
contained all the gels of a given experiment. A standard image (synthetic) was chosen 
from the Matchset gels, which was used as a reference gel in order to compare data. 
This was usually the gel image that contained the maximum number or most clearly 
defined spots. A particular Matchset could contain about a hundred gel images. The 
greater the number of images generally equates with a more difficult and arduous 
analysis, as the sub-window for viewing a particular spot in all the gel images of a 
particular Matchset becomes progressively smaller. 
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Figure 19: An example of a created Matchset with the top left hand image representing the 
reference image. 
In our experiment, a total of nine Matchsets were created, as determined by the needs 
of the study (see Table 7). The last three mentioned Matchsets were based  on the 
CBvNB_So13 template. Once a Matchset had been created and a standard template 
selected, matching of spots was conducted. 
a. Land-marking and auto-matching 
This was performed firstly by annotating well-resolved spots that were present 
consistently in all gel images as landmark spots and confirmed by studying  the region 
at different levels of magnification. Spots were land-marked at all corners of the gel 
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images by selecting 'landmark' from the match menu, match toolbar or by right 
clicking and selection. The cursor moved along each gel image placed at the 
corresponding point and land-marked spots are displayed as a green triangle. The 
programme then by default performed an auto-match once at least two spots in each • 
gel image had been land-marked. Auto-matched spots were displayed as green letters 
in lower case and unmatched spots as red ellipses. 
b. Manual matching 
Unmatched spots, could be manually matched by a similar process by selecting 
'manual match' from the match toolbar. This did not alter the configuration of the 
match that was determined by the previous placement of landmark spots. These spots 
represent those that the computer had failed to recognize in the previous auto-match 
due to minor shifts in position. 
c. Adding unmatched spots to the standard 
Spots that failed to be recognized in the auto-match and those that could not be 
accounted for by manual matching were generally those not present in the gel image 
chosen as the standard. These spots were added to the standard image by similarly 
selecting 'add spot to standard' from the match toolbar and the spots could then be 
manually matched if possible. Spots that could not be manually matched were then 
seen as unique spots. 
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d. Ascribing molecular weight and pI values 
During the run of experiments, standard proteins were required with known molecular 
weight and pI values in order to assign these parameters to the respective protein spots 
of interest. In the first dimension run this was done by the simultaneous focusing of a 
group of standard proteins with known pI values on an fPG strip. This enabled us to 
calculate the pI values of unknown proteins in our experiment by comparison. In the 
second dimension run however, a slightly different approach was utilized. To the left 
of the focused IPG strip placed in its well in the pre-cast gel cassette was placed a 
filter paper wick approximately lOmm in length soaked in 10microlitres of precision 
protein molecular weight standards. The standard proteins would separate alongside 
the experimental proteins in horizontal bands running down the left border of the gel. 
These standards were pre-stained with Coomassie blue and hence were visible even 
prior to staining with silver. 
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Figure 20: Ascription of Molecular weight and pI data onto a reference image (with the first 
number denoting Molecular weight followed by pI). 
2.12 REPLICATE GROUPS AND ANALYSIS SETS 
Analysis sets were then created in order to seek a particular group of proteins of 
interest. However, for our purposes it was not enough to elucidate the differential 
expression of proteins in one gel versus another in the Matchset. Our objective was to 
determine the differential expression of proteins in breast cancer as a whole. PDQuest 
provides for these requirements in the form of Replicate group analysis whereby all 
the gel images from a particular group of patients are treated as similar. In each of our 
Matchsets, Replicate groups were created depending upon  the needs of the exercise as 
displayed in the table below. 
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Match set Replicate groups 
CBvNB_So13 Cancer breast, normal breast, CIS 
CBvNB_So12 Cancer breast, normal breast 
CBvCN_So13 Cancer breast, cancer node, normal node 
CBvCN_So12 Cancer breast, cancer node, normal node 
ACBvGCB_So13 Australian cancer breast, Greek cancer 
breast 
Familial_Sol3 Familial cancer breast (first/second 
degree), cancer breast 
Histosubtype_So13 Ductal cancer, lobular cancer, mixed 
Clinicalstage_So13 Normal breast, CIS, clinical stages I, HA, 
JIB, IIIA, MB (AJC) 
Table 4: Required Matchsets and Replicate groups. 
Once Replicate groups were created, the average spot quantities in the members of the 
group were sought by selecting the quantitation mode as Replicate group quantitation. 
This was located under the Edit menu. With replicate group quantitation each 
individual spot's quantitation was displayed by selecting the quantity table function 
on the spots menu. The average value of that spot's quantitation was then displayed 
along with the co-efficient of variation and the number of gels in the replicate group. 
In order to accurately compare spot quantities between different gels, compensation 
must be made for variation in spot density that was not due to differential expression. 
This is referred to as Normalization. With a Match set open, the normalize button was 
selected from the Analysis menu. The particular method chosen was 'Total quantity in 
valid spots' (as sample load was consistent) with a scaling factor of PPM (parts per 
million). 
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Figure 21: The Normalization sub-window using a scaling factor of PPM (parts per million). 
Having normalized gel data, we were now ready to begin analysis. The 'create 
Analysis set' button was selected from the Analysis menu or toolbar. To begin with, a 
'Quantitative Analysis set' was created by clicking on the 'Type' button  and selecting 
the required Analysis set type in order to perform fold change analysis. The next step 
was to select Replicate groups (A and B) for comparison using the compare command 
and selecting the required group from the drop down menu. We could now dictate the 
fold change requirements of the experiment. In order to obtain spot data  that was 
significant a fold change factor was selected depending on the number of spots in the 
set and the need for a fold change that was statistically significant. This was usually of 
the order of 5 fold. By then clicking on the 'Go' button, the 'Create Analysis set' 
dialog box was replaced by the Match set standard image containing the highlighted 
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Name 11C13vNB_So13_5fold 
Description I 
Type I Quantitative 
Compare Gels 
Increased 
13] 
Increased or 
Decreased 
Select spots 
which are 
Decreased B<Aover 15.00 	Conserved 
AB 
Units Quan. units OD*Area 	 Norm. units PPM Basis All valid spots 
Go I 	Cancel 
spots that met the above criteria. For example, if the 'Increased in A' button was 
clicked and a factor of 5.00 was entered, this would include spots in the Analysis set 
whose quantitation was at least five times that of the corresponding spot in  B. 
Similarly, clicking on the 'Decreased in A' button and entering a factor of 5.00 would 
include spots in the Analysis set whose quantitation was less than a fifth of that of the 
corresponding spot in B. 
Create Analysis Set 
Figure 22: The Create Analysis Set dialog box denoting a Quantitative Analysis Set with a five-
fold sensitivity. 
For the purposes of analysing spot data that was present in already defined Analysis 
sets, Boolean Analysis sets were created using Boolean operators. This was 
performed by clicking on the 'Type' button on the 'Create Analysis set'  dialog box 
and selecting Boolean. The wanted Analysis sets for comparison were selected along 
66 
•  Create Analysis Set 
Name 
Description 
'conserved and 5-fold 
 
  
 
Type I Boolean 
ncreaseCNvNN5-fold 
Compare I sets 
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Go I 	Cancel 
'...■•■•■1■■, 
Only in AI CO 
Only in B I OD 
B I IconservedCBC115-fold 
'Common GD 
In both I CD 
Unique I COD 
with the Boolean operator required. By then clicking on the 'Go' button, the 'Create 
Analysis set' dialog box disappears, to be replaced by the Match set standard image 
containing the highlighted spots that meet the above criteria. 
Figure 23: The Create Analysis Set dialog box denoting Boolean operators. 
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2.13 LIST OF REAGENTS 
Reagent Amount (final concentration) 
Urea 9.61gm (8M) 
Trizma base 0.1gm (40mM) 
CHAPS 0.8gm (4% w/v) 
Bio-Lyte 3/10 Ampholyte 40microlitres (0.2% w/v) 
MilliQ Adjust to 20m1 
Table 5: Reagent 2. 
Reagent Amount (final concentration) 
Urea 6.01 gm (5M) 
Trizma base 0.1 gm (40mM) 
Thiourea 3.04 gm (2M) 
CHAPS 0.4 gm (2% w/v) 
SB 3-10 0.4 gm (2% w/v) 
Bio-Lyte 3/10 Ampholyte 40microlitres (0.2% w/v) 
MilliQ Adjust to 20m1 
Table 6: Reagent 3. 
Reagent Amount (final concentration) 
Urea 36gm (6M) 
20% SDS 10m1 (2%) 
1.5M Trizma base 3.3m1 (0.05M) 
50% Glycerol 40m1 (20%) 
MilliQ Adjust to 100m1 
Table 7: Equilibration base buffer. 
Reagent Amount 
Trizma base 30.28gm 
Glycine 144.14gm 
SDS 10gm 
MilliQ Adjust to llitre 
Table 8: Tank Buffer. 
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Reagent Volume 
Methanol 200m1 
Acetic Acid 40m1 
Fixative Enhancer 
Concentrate 
40m1 
MilliQ Adjust to 400m1 
Table 9: Fixative Enhancer Solution. 
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3.0 RESULTS 
3.1 PATIENT DATA 
The following Table details patient and sample data from the Tasmanian study group 
comprising patients of largely Anglo-Celtic background. In total, 28 breast cancer 
samples were obtained, of which 26 were invasive cancer samples. In some cases, as 
mentioned below, patients provided nodal cancer, normal breast and nodal tissue 
samples. All patients in the group were female and no samples of malignant or 
normal, breast or nodal tissue were obtained from male patients. 
70 
Sample 
ID Age Histology TNM stage 
Receptor status Pre-operative 
therapy Oest Prog c-erbB2 
1 80 NOS T2N0M0(IIA)+ + + - XRT 
2 87 Ductal T2NOMO(IIA) + + - 
3 75 Ductal T2NOMO(IIA) + + - 
4 53 Mixed T2NOMO(II) + - - 
5 50 Ductal T3N2M0(IIIA) * - - +++ 
6 77 Ductal T2NOMO(IIA) ++ + +++ 
7 49 Ductal T3N2M0(IIIA) + - - Chemotherapy 
8 64 Lobular T2NOMO(IIA) NP NP NP 
9 47 Mixed T2N1M0(IIB) * + + - 
10 78 Ductal T1NOMO(I) + +1- - 
11 65 Mixed T1NOMO(I) + + NP 
12 59 Ductal T1NOMO(I) ++ - NP 
13 87 Lobular T2NOMO(IIA) + + NP 
14 91 Ductal T2NOMO(IIA) + + NP 
15 70 Ductal T1N0M0(I)+ + + NP 
16 67 Ductal TN0M0(0)+ + + NP 
17 80 Ductal T1NOMO(I) + + - NP 
18 68 Ductal T1NOMO(I) + + NP 
19 51 Ductal T1NOMO(I)+ - 
20 61 Lobular T2N1M0(I113)± + +1- - 
21 62 Ductal T1N0M0(I)+ + + NP 
22 44 Lobular T2N1M0(III3) + + - 
23 82 Ductal T2N2M0(IIIA) * + + - 
24 79 Lobular T3N0M0(IIB) + + + NP 
25 61 Ductal TisN0M0(0) + - NP 
26 74 Tubular T1N1M0(IIA)+ + + NP 
27 64 Ductal T4N2M0(II1B) * - - NP 
28 87 Ductal T2N1M0(III3) NP NP NP 
Table 10: Tumour characteristics of Tasmanian group with dominant histology, clinical stage 
(TNM and AJC), receptor status and relevant pre-operative treatment. XRT=radiation 
treatment, NOS=Not otherwise specified, NP=Not performed, *denotes nodal cancer tissue 
obtained, +denotes normal node tissue obtained. 
The table below details salient family history and pre-operative treatment 
characteristics. 
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Patient ID 
Family 
history Pre-operative  therapy Menopause HRT 1° 2° 
1 - - XRT Post - 
2 - - - Post + 
3 - - - Post - 
4 - + - Post + 
5 - + - Pen i - 
6 + - - Post - 
7 - - Chemotherapy Pre - 
8 - - - Post + 
9 + - - Pen i - 
10 - - - Post - 
11 - - - Post - 
12 - - - Pen - 
13 - - - Post - 
14 - + - Post + 
15 - - - Post - 
16 - - - Post - 
17 + - - Post + 
18 - - - Pre - 
19 - - - Pre - 
20 - - - Pen i - 
21 - - - Pen i - 
22 - - - Pre - 
23 - - - Post - 
24 - - - Post - 
25 - - - Pen i - 
26 - - - Post + 
27 + - Post + 
28 - - Post - 
Table 11: Further patient data including family history and relevant menopausal and pre-
operative treatment characteristics. 
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Sample ID Age Concurrent tumour in ipsilateral breast 
1 32 - 
2 80 + 
3 87 + 
4 69 - 
5 87 + 
6 57 - 
7 39 - 
8 24 - 
9 32 
10 44 - 
11 71 
12 43 
Table 12: Normal breast tissue samples obtained for this study. 
As mentioned above, a total of 12 samples of normal breast tissue were obtained from 
the Tasmanian population. Of these, 9 were from patients having undergone reduction 
mammoplasty and the remaining were normal breast tissue samples from patients who 
had undergone mastectomy for cancer. 
For the purpose of accurate spot quantitation throughout Matchset member gels, it 
was important to load a standard amount of protein. This was performed mainly by 
using a standardized sample weight of 100mg, after removing any macroscopically 
evident fat tissue as alluded to in the methods section. However, another way of 
testing this was to perform a modified Bradford assay and this was performed using 
randomly chosen cancerous and normal breast samples, showing grossly similar 
spectral absorbance. 
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3.2 BREAST CANCER 
As detailed above in the methods section, a number of Matchsets, with their contained 
replicate groups were created in order to answer a particular question. Within these 
Matchsets were contained analysis sets that displayed the requisite spot data. As 
displayed in Figure 24 below the Matchset CBvNB_Sol3 standard Gaussian image 
contains identified spots from cancerous breast and normal tissue of solution 3 
extraction. A total of 403 protein spots (not including molecular weight markers) were 
identified. The highlighted spots indicate quantitative analysis sets increased and 
decreased 5-fold respectively. By these means, 30 spots were found to show a 
minimum of a 5-fold increase (including 8 spots showing a 10-fold increase) in 
expression for cancerous breast tissue versus normal breast tissue. Conversely 15 
spots showed a minimum of a 5-fold decrease (including 1 spot showing a 10-fold 
decrease) in expression in cancerous breast tissue versus normal breast tissue. The 
majority of proteins identified were found to have a molecular weight of 25-75kDa 
(kilodaltons) and lie within a pI range 6.0-8.2 respectively. In this context it was noted 
that gel images obtained from a more malignant phenotype displayed spots showing 
increased expression located towards the basic end of the gel image and spots 
showing decreased expression located towards the acidic end of the gel image, 
whereas the converse was true with gel images from a normal phenotype. 
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, The second extraction step in sample preparation yielded the Matchset CBvNB_So12. 
This revealed a further 24 spots showing a minimum 5-fold increase (including 5 
spots showing a 10-fold increase) in expression in cancerous breast tissue versus 
normal breast tissue. Similarly, 5 spots showed a minimum 5-fold decrease (including 
1 spot showing a 10-fold decrease) in expression in cancerous breast versus normal 
breast tissue. 
Although not a major point of focus in this study, two patients provided non-invasive 
cancer samples and as mentioned earlier, were studied as a distinct replicate group in 
Matchset CBvNB_So13. Although limited by sample numbers, their analysis revealed 
a quantitative 5-fold increase in expression of 8 spots and a 5-fold decrease in 
expression of 6 spots in DCIS (ductal carcinoma in situ) versus normal breast tissue. 
This correlates with data obtained from analysis of invasive cancerous breast tissue 
with some spots in common between the two sets, particularly the cluster between 25- 
37IcDa and pI 7.8-8.2, suggesting that these proteins were expressed early in the 
course of tumour biology. 
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3.3 FAMILIAL BREAST CANCER 
As mentioned in Table 11 (pg 72), 7 patients were identified in the database who gave 
a family history of breast cancer, including 4 with a first degree family history. Their 
analysis was conducted by the creation of Matchset familial_So13 containing the 
replicate groups of familial breast cancer (first/ second degree) and cancer breast as 
mentioned in the methods section. A quantitative analysis set was then created using a 
factor of 2-fold differential expression between familial breast cancer and non familial 
breast cancer. Figure 25 displays 27 spots showing a minimum 2-fold increase in 
expression in familial breast cancer versus non-familial breast cancer, whereas 54 
spots showed a minimum 2-fold decrease in expression in familial breast cancer 
versus non-familial breast cancer respectively. 
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3.4 HISTOLOGICAL TYPING 
Using the Matchset CBvNB_So13 as a template, a further Matchset was created 
(Histosubtype_So13) containing the replicate groups ductal cancer and lobular cancer. 
These were quantitatively analysed using a minimum of 5-fold differential expression 
versus normal breast tissue. Figure 27 below details the quantitative identification of 
26 spots that showed a 5-fold increase in expression in ductal cancer samples versus 
normal breast tissue and 19 spots that showed a 5-fold increase in expression in 
lobular cancer samples versus normal breast tissue. By analysing this data using 
Boolean parameters, it was determined that 15 of the 26 identified spots were unique 
to ductal cancer, whereas 8 of the 19 identified spots were unique to lobular cancer. 
Figure 26: Boolean analysis of quantitative sets Increased in ductal cancer 5-fold and Increased 
in Lobular cancer 5-fold showing 15 unique spots in ductal cancer and 8 unique spots in lobular 
cancer respectively. 
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3.5 CLINICAL STAGE 
In order to study the differential expression of protein spots in sequence with tumour 
biological progression, Matchset Clinicalstage_So13 was established based on the 
CBvNB_So13 template. A 5-fold quantitative analysis was performed between the 
various clinical stages of breast cancer (based on the AJC classification) samples 
obtained by the creation of appropriate replicate groups within the Matchset as 
mentioned in the methods section. The figure below accounts for a logical stepwise 
change in the spot expression profile with clinical stage progression. A total of 96 
protein spots have shown stage differentiated quantitation. 
Differential expression by clinical stage 
Figure 28: The differential expression of spots by clinical stage as studied in Tasmanian breast 
cancer group (Matchset Clinical stage_So13). 
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3.6 RACIAL DIFFERENTIATION 
A total of 16 breast cancer samples were obtained from Athens and their salient 
features are mentioned below. No samples of nodal cancer, or normal breast/ nodal 
tissue were obtained. 
Sample 
ID Age Histology TNM stage 
Receptor status Pre-operative 
therapy Oest Prog c-erbB2 
1 54 Mucinous T1NOMO(I) +++ +++ - 
2 71 Ductal T1N1M0(IIA)± +++ ++ ++ 
3 61 Ductal T1NOMO(I) +++ +++ + 
4 51 Lobular T1NOMO(I) * ++++ ++ + 
5 61 Ductal T3N2M1(IV) ++ + +++ 
6 64 Ductal T2N1M0(IlB) ++ - +++ 
7 58 Lobular T2N2M0(IIIA) ++ + + 
8 46 Ductal T1N1M0(IIA) * +++ + + 
9 75 Ductal T2N1M0(I1l3) ++ + + 
10 57 Ductal T1N1M0(IIA) +++ ++ +++ 
11 54 Ductal T3N2M0(IIIA) +++ ++ ++ Chemotherapy 
12 81 Ductal T3NOMO(IIB) - - - 
13 67 Ductal T2N2M0(IIIA) + + + 
14 80 Ductal T1NOMO(I) +++ ++ ++ 
15 65 Ductal T1NOMO(I) ++ ++ - 
16 78 Ductal T1M0(I) - ++ - Tamoxifen for 
6yrs, Re-
operation for 
local 
recurrence 
Table 13: Tumour characteristics of Athens group of patients with dominant histology, clinical 
stage (TNM and AJC), receptor status and relevant pre-operative treatment. *denotes first 
degree family history of breast cancer, 'denotes second degree family history of breast cancer. 
Matchset ACBvGCB_So13 contains differential spot data between gels processed 
from Tasmanian and Athens group breast cancer samples. A 2-fold quantitative 
analysis was conducted of these replicate groups to reveal the increased expression of 
43 spots and decreased expression of 37 spots in Tasmanian breast cancer. Further 
analysis revealed 5 of 43 spots showing a minimum 5-fold increase and 3 of 37 spots 
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showing a minimum 5-fold decrease in expression in Tasmanian breast cancer, 
respectively. 
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Extraction 2 contributed towards the production of gel Gaussian images contained in 
Matchset ACBvGCB_So12. The analysis of this reveals a quantitative 2-fold increase 
in the expression of 29 spots, of which 3 displayed a minimum 5-fold increase in 
Tasmanian breast cancer samples versus Athens group breast cancer samples. 23 spots 
were found to display a minimum 2-fold decrease in expression in Tasmanian breast 
cancer samples. 
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3.7 METASTATIC PHENOTYPE 
Node positive disease enabled the study of the metastatic potential of breast cancer. A 
total of five patients only, provided nodal cancer tissue samples, whereas another nine 
patients provided normal node tissue (Table 10, pg 71). Matchset CBvCN_So13 was 
created containing the replicate groups of Tasmanian breast cancer, nodal cancer and 
normal nodes as described in the methods section. A quantitative analysis set was then 
created looking at all the spots that were conserved between Tasmanian breast and 
nodal cancer within a 2-fold sensitivity. These amounted to 95 spots in total. These 
spots could not be present to any significant degree in normal nodes and hence, 
further quantitative analysis sets were created to reveal a minimum 2-fold increase in 
expression of 31 spots, of which 11 spots displayed a minimum 5-fold increase in 
expression in nodal cancer versus normal nodes. By Boolean analysis of these sets, 11 
spots were found to be conserved in nodal cancer and showed a minimum 2-fold 
increase when compared to normal nodes. Of these spots, 2 were found to show a 5- 
fold increase in expression in nodal cancer. 
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The quantitative and Boolean analysis of the corresponding Solution 2 Matchset 
CBvCN_So12 revealed 40 spots that were found to be conserved between Tasmanian 
breast and nodal cancer within a 2-fold factor. Of these, 8 spots were found to show a 
2-fold increase in expression when compared to normal nodes, with 4 of these 
showing a 5-fold increase. 
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4.0 DISCUSSION 
4.1 STUDY DESIGN 
With the burgeoning rise of proteomic technology in the last decade, it became clear 
that this science could be applied to the study of a large variety of disease conditions 
including cancer. As such, breast cancer as a disease state had not been extensively 
studied using this technology with reports in the literature being relatively few in 
number [51, 73]. Secondly, it was felt that the analysis of intact tumour tissue would 
be more representative of the disease state in the community as alluded to by Giometti 
et al, as opposed to the previously studied cultured breast epithelial cell lines [52]. 
The incidence of breast cancer in Tasmania as detailed in the literature review was 
consistent with the national average. Background knowledge into the aetiological 
significance of breast cancer was lacking, with little objective clinical evidence to 
corroborate. However, the purpose of the study was to establish a baseline proteomic 
profile of the disease that could then be analysed to find potential diagnostic markers 
and therapeutic targets not unlike the history of the development in OR and HER-2 
receptor modulation. In order to do this, a larger patient population translating to more 
tissue samples would have been ideal but not entirely necessary and we were able to 
obtain, what was thought to be, a sufficient number. Further, in order to expand our 
sphere of study, we chose firstly, to include patients undergoing axillary dissection 
and obtain nodal tissue for comparison. This would attempt to identify a metastatic 
phenotype of breast cancer. However, the proportion of breast cancer patients 
providing for malignant nodal samples was under-represented. This was not 
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unexpected and is likely to be an ongoing concern in any experiment of this nature. 
The reasons for this are multifactorial. Firstly, with an earlier stage at diagnosis, fewer 
patients are likely to present with malignant axillary nodal disease translating to a 
trend towards breast conservation surgery and nodal sampling techniques. Secondly, it 
was found that this also meant that with the smaller number of nodes provided for 
pathological examination, it was less likely that a node would be obtained for our 
experiments. 
In order to consolidate our existing patient database and to highlight possible 
differences in expression between racially diverse population groups, we sought 
assistance from overseas colleagues. The opportunity thus arose to obtain breast 
cancer samples from the Prolipsis clinic in Athens, Greece. The lack of a control 
group from within this population was seen as a limiting factor but the logistical 
difficulties in solving this were not deemed practicable and any significant findings 
obtained would need to take this into account. We had earlier approached colleagues 
from Japan, but due to a change in legislature in that country and an effective ban on 
the export of human tissue for experimental purposes, this avenue did not materialize. 
We then sought other colleagues from Taiwan, from whom we were successful in 
obtaining tissue. However, due to time constraints, this group has been excluded from 
this thesis. The preparation and analysis of these samples is ongoing and with time 
this shall aid in the production of a more comprehensive proteome map of the disease. 
To the author's knowledge, the study of breast cancer from epidemiologically distinct 
population groups has not been investigated previously. 
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4.2 SAMPLE PREPARATION 
It was realized that the most convenient method of sample preparation, given the time 
constraints of the study, was to use previously established protein separation 
protocols. The Bio-Rad corporation has conveniently formulated the 2D starter kit 
(catalogue no. 163-2105) including a protein sample (E.coli whole cell lysate) and 
sufficient reagents to re-hydrate, focus and transfer to the second dimension gel, ten 
11 cm ReadyPrep lPG strips [67]. Although the use of this kit was not included in our 
protocol, it did however serve as a training tool and provided for a backup source of 
reagents. However, the fact that reagents were individually prepared in the laboratory 
in batches does also raise the possibility of a theoretical difference in chemical 
concentrations amongst reagents. 
It has been.well known that reproducibility of sample preparation is the key to a 
successful proteomics experiment [74]. However, as mentioned previously, there has 
been little work in the past on intact breast tissue. As stated by Bio-Rad, most protein 
mixtures will require some experimentation to determine optimum conditions for 2D-
PAGE [67]. The 2D starter kit and ReadyPrep sequential extraction kits (see methods 
section) provided readymade reagent solutions for training. For this purpose, tissue 
from our already established breast tissue bank was not suitable. As an alternative to 
the E.coli cell lysate provided with the starter kit, we chose to use an animal protein 
source and the most suitable, was commercially available chicken breast without the 
exclusion of subcutaneous fat. Samples were prepared according to the protocols 
established by Bio-Rad and gels produced by their two dimensional electrophoresis 
showed adequate spot identification, although a large section of the gel was occupied 
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by myosin chains. Analysis of these images was not conducted. The next step was to 
determine how normal breast tissue would behave under these circumstances. 
Homogenization of sample, which was quite easy with chicken breast proved to be a 
challenge with intact normal breast tissue. The UltraTurrax (see methods section) 
electric homogeniser was not suitable for, in particular, normal breast tissue that 
would continually entwine itself in the instruments blade apparatus. The only suitable 
alternative was to transfer the contents to a Pyrex manual homogeniser (see methods 
section), which although laborious, provided for a satisfactory homogenisation. This 
process needed to be interrupted momentarily every 2-3 minutes because generated 
heat in the homogeniser necessitated placement of sample in the freezer for cooling. 
Malignant breast tissue on the other hand, when subjected to homogenisation behaved 
unexpectedly. This tissue would fragment quite easily in the manual homogeniser and 
hence this was the preparation method of choice for all obtained cancer samples. 
Admittedly, it would not be entirely implausible for this variation in preparation 
technique to have accounted for some of the differences in gel pattern between normal 
and cancerous breast tissue. 
Sequential extraction is a means to sample solubilization and reducing sample 
complexity. As stated by Molloy MP et al, increasingly powerful solubilizing 
solutions used in sequence have been shown to increase the total number of spots 
detected [54]. These solutions extract an overlapping set of proteins. Reagent 1 
(containing 40mM Tris) extracts soluble proteins such as cytosolic proteins, whereas 
Reagents 2 and 3 (containing differing concentrations of chaotropic agents, 
detergents, carrier ampholytes and reducing agents) extract proteins of intermediate 
and low solubility. Urea and Thiourea are commonly used chaotropic agents that 
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disrupt hydrogen bonds and prevent the formation of protein aggregates. Detergents 
such as CHAPS disrupt hydrophobic interactions and increase the solubility of 
proteins at their respective pI [67]. Newer detergents have emerged such as SB 3-10 
(see methods section) and ASB-14 that have helped isolate previously undetected 
membrane proteins and have found increasing use in proteomics experiments [75]. 
Each of the three reagents extract an overlapping set of proteins and greatly increase 
the number of protein spots identified, however as mentioned in the methods section, 
Solution 1 was not processed beyond the preparation stage in order to exclude 
potentially interfering abundant cytosolic proteins. 
The role of carrier ampholytes lies in the supplementation of salt concentration in a 
sample solution. Certain proteins require salt for adequate solubility but the 
concentration of these salts is usually restricted to 40mM as they limit the applied 
voltage and hence increase the time required for focusing. Their concentration is 
therefore limited to <0.2% w/v and in our experiment, were used as a mixture over a 
large pH range (3-10). We experimented with the idea of using a mixture of carrier 
ampholytes and these would have been over a pH range of 5-8 and 8-10 in a ratio of 
2:1. However, to avoid repeating all the experiments in our limited given time frame 
and the delay in transport of ampholyte solutions from the Bio-Rad Corporation in the 
U.S.A., this was not able to be performed. 
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Figure 33: Matching sections of 2D images showing separation of 110 micrograms of a cytosolic 
extract of human lymphoblastoid cell line loaded on a 17 cm pH 5-8 ReadyStrip 1PG strip and 
second dimension separation on a 10-24% gradient gel. Image B shows greatly improved 
focusing with the use of pH 5-8/8-10 ampholyte mixture in a ratio of 2:1 [67]. 
The use of reducing agents such as DTT (Dithiothreitol, used in IPG strip 
equilibration, see methods section) and TBP (Tributylphosphine, used in Reagents 2 
and 3, see methods section) reduce disulfide bonds and increase spot resolution [62]. 
We found that increasing the concentration of TBP to 20microlitres or a  1:50 dilution 
from the prescribed 1:100, significantly increased spot resolution and that increasing 
it further to a 1:25 dilution did not aid greatly, but substantially increased the 
utilization and cost of the volatile reagent [67]. 
4. 
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The new and more powerful detergents, the use of a variable mixture of carrier 
ampholytes and reducing agents shall aid greatly in the production of more clearly 
resolved gel images. 
The presence of nucleic acids, particularly DNA, was found to interfere with adequate 
sample preparation. The DNA complexes would markedly increase the viscosity of 
the sample solution and hinder protein entry and migration on the IPG strip. As 
mentioned earlier, this was particularly the case with lymph node samples, with 
protein spots at times showing poor separation on 2D gels. The use of endonuclease 
helped overcome this problem. 
4.3 TWO DIMENSIONAL PAGE 
Resolution in the first dimension run is dependent on the pH gradient, strip length and 
the applied electrical field. As stated by Garfin et al, the difference in pI (Iso-electric 
point) between two adjacent IEF resolved protein bands is directly proportional to the 
square root of the pH gradient and inversely proportional to the square root of the 
voltage gradient at the position of the bands [76]. In simpler terms this theory states 
that, band resolution will be maximal in narrow pH ranges when high voltages are 
applied. One of the drawbacks of this statement is that, with high applied voltages, 
heat is generated. Hence, for the sake of not compromising resolution, thin IPG gel 
strips are preferred as they dissipate heat more readily [67]. Thin IPG strips have been 
the benchmark tool for the first dimension focus during the last 15 years. 
- 
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The advent of `zoom-in' narrow range (pH 4-7, 5-8) and very narrow range (pH 4.5- 
5.5, 5-6) LPG strips have added greatly to the resolution of a first dimension run. Of 
late, it has become increasingly clear that, additional resolving power is needed to 
separate complex eukaryotic proteomes [65, 77]. Our laboratory has recently acquired 
narrow range IPG strips (pH 5-8) and these shall help increase spot detection. 
A pre-requisite to the second dimension run is the equilibration of IPG strips and this 
ensures that proteins are coated with Dodecyl Sulfate and Cysteines are reduced and 
alkylated. We found it more convenient to use 2.5% DTT in our protocol (see 
discussion of sample preparation) both for ease of base buffer preparation and 
increased resolution compared to the prescribed 2% concentration [67]. The loading 
of 1PG strips onto its well in the Criterion 2D gel cassette was also complicated by the 
delayed binding of low melting point Agarose overlay solution when used at the 
prescribed concentration of 0.5%. We found that a 1% solution avoided migration of 
the IPG strip and marker proteins as well as the unnecessary waiting period while the 
Agarose set. 
Our decision to use gradient gels for the second dimension run was based on the need 
to analyse proteins over a large molecular weight range and perform a global 
comparison of gels. The next logical step in our experiments would have been to 
perform the second dimension run on narrower gradient or single percentage precast 
Criterion gels e.g. 12.5% resolving, 4% stacking (total percentage of Acrylamide plus 
cross-linker) (Bio-Rad, catalogue no. 345-0018) that would resolve proteins within a 
mass range of 20-100kDa. This would help the further resolution and detection of 
spots within the molecular weight range of virtually all our currently detected spots. 
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Another feature that would aid high-throughput experiments would have been the use 
of Criterion Dodeca cells (Bio-Rad, catalogue no. 165-4130) capable of 
accommodating 12 gels per run, although for our purposes this would have equated 
with a substantial increase in cost and a more tedious experiment given limitations in 
other associated equipment and manpower, and hence not seriously considered. 
Gel staining techniques also needed to be adapted to suit laboratory conditions. The 
Criterion precast gel cassettes are packaged in appropriately sized plastic containers 
and these proved to be ideal staining vessels, the only limiting factor being the size of 
the laboratory platform mixer. This restricted the number of gels that could be stained 
at any one time to six. The protocol we followed for Silver Stain Plus was largely, as 
described by Bio-Rad. This was a modification of the standard silver stain that was 
developed in the late 70's by Merrill eta!, and various commercially available kits are 
available, each with their own protocols [78, 79]. Essentially, the use of Silver Stain 
Plus enables the mass spectrometric analysis of excised spots that standard stain does 
not. This is due to an additional oxidative step in standard silver staining technique 
that changes protein mass. There is a drawback however, in that the visualization of 
heavily glycosylated proteins and lipoproteins can be less sensitive with Silver Stain 
Plus. Staining results were variable, depending on the quality of sample prepared. The 
quality of gel images obtained was also dependant on the period of time incubated in 
stop solution (5% Acetic Acid) and the immediate placement of gels in the stop 
solution would highlight spots and potentially give rise to over-stained gels. 
Overnight incubation of stained gels in the refrigerator was also a practice we learnt to 
avoid, as this caused them to enlarge and distort, needing an extended wash with 
milliQ (see storage step, methods section). 
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The sensitivity of Silver Stain Plus has been said to be 30 to 50-fold times that of 
Coomassie Brilliant Blue R-250, the standard stain for protein detection. The 
fluorescent SYPRO Ruby and Orange stains, and radio-isotope labelling have features 
that are desirable in high throughput laboratories. They are sensitive to 1- 
lOnanograms of protein but require costly image acquisition tools. They do however, 
allow detection of glycoproteins, lipoproteins, low molecular weight proteins and 
metalloproteins that are not well detected by other stains [67]. This is also reflected by 
the fact that these stains have shown a greater number of protein database matches 
and percent sequence coverage, as stated by Lauber WM eta! [69]. 
4.4 GEL ANALYSIS 
The acquisition of gel images was conducted by densitometry which measures the 
intensity of a light beam before and after being attenuated by a protein spot. Wet gel 
images could also be acquired by the water-proof scan platen. However, for reasons 
of practicality, we chose to store prepared gels in appropriately sized zip lock clear 
plastic bags containing 2 ml of 5 % Sodium Azide as a preservative. This made gels 
extremely portable and could be handled without a relative fear of breakage. Images 
could then be scanned directly with the gels contained in their zip lock bags and their 
acquisition was not compromised using this method. 
In order to compensate for sample variation, errors in the preparation, loading and 
running of two dimensional gels, it was useful to treat the gels as being similar [67], 
particularly as the biological question in mind was the essential difference between 
malignant and normal breast tissue. This similar treatment was referred to as replicate 
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group quantitation and was necessary to avoid large numbers of analysis sets between 
Matchset member Gaussian images. Spot quantitation was thus reflected as an 
average within a particular group and made for a more accurate quantitation. The 
disadvantage of using this approach was that, as mentioned above, spots that were 
qualitatively expressed in one group versus another could not be determined as the 
number of analysis sets required would be too great. A further disadvantage of 
replicate group analysis in the currently used version of PDQuest (v6.2.0) was that it 
failed to recognize a member gel image to be present in more than one replicate 
group, necessitating the creation of multiple copies of a Matchset template. 
We found PDQuest to be a program that required considerable tuition. An enclosed 
self help tutorial CD-ROM was extremely useful. Following a lengthy period of 
familiarization and hands on experience, scan and crop settings, spot detection and 
matching could be performed with relative ease. There are more recent programs such 
as PDQuest version 7.0 (Upgrade catalogue no. 170-8626), Melanie IV and 
ImageMaster 2D Platinum 5.0 that are now available. The latest version of PDQuest 
incorporates the newly developed SPoT (Streamlined PrOteomic Tools) technology 
that entails an auto-matching algorithm, significantly reducing the need for manual 
intervention during matching. In addition, exported TIFF image files can include 
display of analysis overlays and annotations as they appear on screen. These and other 
features including a match summary table and integration with Worksbasemi (Bio-
Rad) bioinformatics database shall greatly facilitate spot detection, analysis and 
identification. 
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4.5 RESULTS 
Standard maps of breast cancer including protein spots from Australian and Greek 
breast cancer samples, normal breast tissue, cancerous and normal node tissue, and 
DCIS were created. A composite map was created, containing a total of 403 protein 
spots when looking at Australian breast cancer and normal breast tissue. It could be 
argued that sample size may have been limited particularly in the case of nodal tissue 
and DCIS. However, the purpose of the study was to primarily isolate the differential 
expression of protein spots in Australian breast cancer samples compared to normal 
breast tissue and for this reason emphasis was placed on such. 
A recognizable pattern of spot expression could be seen in gels between cancerous 
and normal breast tissue and particular clusters of spots could be seen to be associated 
with a more malignant or normal phenotype. A total of 74 spots showed a minimum 
5-fold change in expression between Australian breast cancer and normal breast tissue 
samples. Of these, 54 spots have shown a minimum 5-fold increase in expression in 
breast cancer versus normal breast tissue. Although this number is only likely to drop 
with the exclusion of some spots, this is significant in that other authors such as Bini 
et al have reported finding only 32 spots that showed a differential increase in 
expression in breast cancer versus normal breast tissue [80]. Further, Bini et al 
performed their separation using 18cm Immobiline strips of pH3-10 and 9-16% SDS 
gradient 2D gels [80]. Amongst those 54 spots that we have found however, is a 
cluster of spots, 8 in number between 25-37kDa and pI 7.8-8.2 that were found to be 
up-regulated early in the course of the disease, given that they showed a quantitative 
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increase in expression in gels obtained from DCIS samples. These would be a good 
starting point for further characterization. 
The spot expression profile of familial breast cancer samples may herald the 
identification of a marker for these tumours. The sample size is however, limited with 
only 7 patients in the group displaying a family history of the disease, of which only 4 
displayed a first degree history. Thus, further samples may be required along with a 
more sensitive analysis (2-fold change at present). It is also not known if any of these 
familial breast cancer samples were linked to any of the known genetic breast cancer 
syndromes as none have been tested specifically for such. Nonetheless, a search for 
their translated proteins (including BRCA-1, BRCA-2, p53, Rb, bax, bc1-2) shall be 
conducted and a differential expression sought. 
Similarly, histological sub-typing is associated with prognosis and may have a bearing 
on overall treatment and outcome. As mentioned in the results section, 15 spots were 
found that were unique to ductal cancer and 8 spots that were unique to lobular 
cancer. This has not been previously reported in the literature and further 
characterization may herald the identification of an early marker for histological 
differentiation, although the value of this compared to existing parameters is 
debatable. 
The primary reason for studying these tumours from a view point of clinical stage was 
to attempt to identify an early marker for local invasion and nodal metastases. In 
addition, as Figure 28 in the results section shows, with tumour biological progression 
there are 96 spots that we have found, to have shown a 5-fold change in expression. 
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These spots may represent loss of tumour suppressor factors or conversely, of 
amplification of tumour promoting factors. In which case, tumours would be able to 
be further sub-classified based on the presence or absence of these factors and their 
likelihood of progression to the next clinical stage. An appropriate starting point for 
the investigation of these would be amongst the spots showing a fold change in 
expression between normal, DCIS and early breast cancer. There are in addition, other 
tumour parameters that could be studied and include histological grade that, akin to 
clinical stage differentiation would seek to identify proteins that are differentially 
expressed with biological progression. This has not been looked at previously in the 
reported literature but had to be excluded due to time constraints. 
The analysis of breast cancer from racially diverse origins has shown a minimum 2- 
fold differential expression of 132 spots using Solution 2 and 3 extractions (including 
11 showing a minimum 5-fold change) between the Tasmanian and Athens groups. 
The further characterization of these 11 spots may reveal the results of genetic, 
environmental or hormonal influences that determine the differences in incidence seen 
between the two groups. As per the authors' knowledge, this has not been studied 
previously. Ideally, as mentioned earlier, this ought to have included a cohort of 
normal breast tissue samples from Athens but the logistical difficulties of arranging 
this, persuaded us from including this group. The future addition of breast cancer 
samples from other regions such as Taiwan will serve to complete the full spectrum of 
incidence. 
As mentioned earlier, we found 19 protein spots that showed a minimum 2-fold 
increase in expression in cancerous nodal tissue compared to normal nodal tissue, that 
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were conserved between cancerous breast and nodal tissue, including 6 spots that 
showed a 5-fold change. The significance of this lies in the fact that this approach has 
not been previously reported in the literature. The number of studies looking at the 
metastatic potential of cancer in general has been limited. To this end, Schwalke MA 
et al and Osada T et al have used a 2D PAGE approach to study pancreatic and 
hepatocellular carcinoma respectively, but breast cancer has not been previously 
evaluated [81, 82]. Our attempt was to try and identify protein spots that would be 
differentially expressed in a tumour that was seen as being, more capable of axillary 
metastases. Firstly, this would have benefits in terms of, identification of tumours 
with a greater metastatic potential and thereby identify patients who would benefit 
from a more radical axillary clearance or chemotherapy. Secondly, as mentioned 
earlier, this may allow the identification of a marker of axillary metastases and its 
study as a potential target for the development of an adjunctive therapeutic agent. 
However, there are limitations to the study of nodal disease as also discussed 
previously. 
4.6 FUTURE IMPLICATIONS 
Our experience with proteomic sciences has led us to believe that the refinement of 
spot set data is an ongoing exercise, taking into account the inclusion of further breast 
cancer samples from different sources and with varied phenotypic expression. To this 
effect, it would have been ideal to procure further cancer samples from other 
population groups at the lower end of the spectrum of incidence such as Taiwan to 
add to our current dataset. Although also not feasible for the purpose of this thesis, it 
would have been ideal to have obtained more familial breast cancer and nodal tissue 
109 
samples given the small numbers obtained for the purpose of this study. It would also 
be fair to say that the analysis of our current gel images using the later versions of gel 
analysis software would yield more accurate match and analysis set data. 
In order to find new potential markers and/or therapeutic targets it was deemed vital 
to exclude already known markers of the disease. Although details of this are not 
included in this thesis, we have identified five known prognostic factors and include 
OR- a 13-casein, cytokeratin 7, calponin and bax using a 2DPAGE and Western blot 
approach. It has been interesting to note in this regard that ORa, the most commonly 
studied prognostic factor of breast cancer, was found to be present in two isoforms. A 
63kDa isoform that is detected by currently used immunohistochemical means, was 
up-regulated in cancerous breast tissue samples. The second 80kDa isoform was 
qualitatively expressed in cancerous breast tissue samples and not in normal breast 
tissue samples. This finding presents significant advantages in using a proteomics 
approach rather than conventional techniques [83]. 
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Figure 36: Silver Stain Plus and overlay Western blot obtained molecular weight and pI data for 
selected prognostic factors. ER=estrogen receptor [83]. 
Using this approach it is hoped that other known markers of the disease shall also be 
identified and excluded. 
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The refinement of our current data shall be an ongoing process. Protein spots, as they 
are excluded by comparison, identified by mass spectrometry and/or sequenced, will 
be determined to be, more or less significant to the pathogenesis of breast cancer from 
our knowledge of the disease today. With the advancement of existing software 
available for proteomic analysis, this process is likely to become more precise. 
Enhanced spot identification, editing and matching is likely to produce an easier 
analysis and a more refined spot set. The development of newer integrated tools such 
as the spot excision tool (ProteomeWorks, Bio-Rad) would greatly aid the accurate 
recovery of gel spots (though we will need to resort to sending intact gels to APAF, 
Australian Proteome Analysis Facility for further processing). Bioinformatics 
databases will be the way of the future, but security issues may need to be addressed 
even though many of these require a multi-level secure log-in for entry. These and 
other advancements in the field address the needs of a growing science with great 
potential for the discovery of new potential diagnostic markers/ therapeutic targets, 
not just in breast cancer but any disease. 
As previously discussed in the literature review, the evolution of our knowledge of the 
oestrogen receptor began with its discovery, leading to its significance as a prognostic 
marker and finally becoming a target for modulation. In later years, the exact process 
could be said to have occurred in the case of Herceptin, largely due to the work of 
Slamon et al [33, 38, 84]. Only through the discovery of the OR and HER-2 proteins 
have they evolved into significant prognostic markers and eventual targets for 
modulation. It is hoped that with further investigation and characterization, a similar 
protein be identified that may follow the examples above. We believe that proteomic 
sciences will be the key to this discovery. 
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APPENDICES 
CONSENT FORM 
"Proteome Analysis of Breast Cancer" RHII ethics 2001.02 
Statement by the patient: 
I have read and understood the "Information Sheet" for this research study. I 
understand that breast tissue removed, as a course of my surgical management will be 
provided to researchers involved in this study. I have been informed that the results of 
the study may not be of any direct benefit to my medical management. Any questions 
that I have asked have been answered to my satisfaction. I agree to participate in this 
investigation and understand that I may withdraw at any time without prejudice to my 
future medical care. I agree that research data gathered for the study may be published 
provided that I cannot be identified as a subject. 
Name of Patient: 
Signature of Patient: 
Date: 
Statement by the researcher: 
I have explained this research study and the implications of participation in it, to the 
volunteer patient. I believe that the consent is informed and that she understands the 
implications of participation. 
Name of Researcher: 
Signature of Researcher: 
Date: 
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INFORMATION SHEET 
for patients diagnosed with breast cancer 
"Proteome Analysis of Breast Cancer" 
Dr Roger Lord, Dr Kiron Bhatia & Professor Peter Stanton (Chief Investigators) 
Study procedure and possible risks: 
As you have been diagnosed with breast cancer and have been scheduled for surgery 
to remove the tumour, you are invited to participate in the study. There are no 
additional risks in being involved in this study nor are there any additional procedures 
that will take place. Your consent is sought purely for the scientific use of the tissue 
being removed. 
Purpose of Study: 
The aim of this project is to produce a basic protein map of breast tissue, be it 
cancerous or otherwise normal. The researchers of this proposed study seek firstly, to 
look at differences in known biological markers of breast cancer between two 
populations of women, one group from Japan and the other from Australia. Women 
from Asian regions have a much lower mortality rate for breast cancer when 
compared to those in Australia. It has been suggested that environmental and/or 
dietary factors may account for this observation but as yet there is no data to clearly 
indicate that this is the case. If biological differences between these groups do exist, 
then these might present as higher or lower levels of known biological markers of the 
disease. 
The second part of the study uses a state of the art separation method that allows 
complex mixtures of molecules to be resolved. Using this method a biological map of 
all the molecules that make up a piece of tissue, such as a breast cancer, can be 
separated to produce a map, which is unique for that tissue. Normal breast tissue (e.g. 
from women under going breast reduction) would thus have a different map to breast 
cancer or for that matter advanced cancers that have broken away from the main 
breast tumour and begun to grow in another region of the body. The differences 
between maps for the normal breast tissue compared with cancerous tissue may 
represent molecules that have been generated as a result of the cancer. These 
molecules could be markers of the disease or targets for future vaccines or 
pharmaceutical drugs. 
Inclusion or exclusion criteria for this research project: 
This study includes patients who are either having a breast cancer removed, including 
any advanced cancers that have spread to the lymph nodes and women under going 
breast reduction surgery. There are no exclusion criteria for this project. 
Participation and withdrawal from the research project: 
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Participation in this research project is entirely voluntary and no financial payment 
will be given. If you decide to take part in this study, there will be no prejudice 
against your future care if you decide to withdraw prior to surgery. 
Confidentiality: 
Information and materials obtained during this project will remain strictly confidential 
and shall only be used for the purposes of this study. Only the investigators directly 
involved in this project will have access to identifying data. The Privacy Act, 1988 
gives this research project the guidelines for conduct. Your consent to participate in 
this research project will be an informed one and the investigator will answer any 
questions you have. Any unused tissue may be kept for future analysis in relation to 
this study alone, and will be disposed of in a professional manner when no longer 
required. 
Information Sheet and Consent Form: 
Copies of the information Sheet and signed consent forms will be given to you to 
keep. 
For more information about this research project, you can contact: 
Dr Roger Lord 
Discipline of Surgery 
GPO Box 252-28 Hobart 
Tasmania 7001 Australia 
Tel (03) 6226 4896 
Email: John.Lord@utas.edu.au  
Dr Kiron Bhatia 
Discipline of Surgery 
GPO Box 252C-28 Hobart 
Tasmania 7000 Australia 
Tel (03) 6226 4875 
Email: kdbhatia@postoffice.utas.edu.au  
If you have any concerns of an ethical nature or complaints about the manner in 
which the project is conducted, you may contact the chair of the Ethics 
Committee: 
Dr Rosalie Parton 
6222 8226 
or 
Chris Hooper 
Secretary, RHH ethics committee 
6226 2763 
122 
INFORMATION SHEET 
for patients undergoing breast reduction surgery 
"Proteome Analysis of Breast Cancer" 
Dr Roger Lord, Dr Kiron Bhatia & Professor Peter Stanton (Chief Investigators) 
Study procedure and possible risks: 
As you are to undergo breast reduction surgery, you are invited to participate in this 
study so as to provide normal tissue for comparison with breast cancer tissue. There 
are no additional risks in being involved in this study nor are there any additional 
procedures that will take place. Your consent is sought purely for the scientific use of 
the tissue being removed. 
Purpose of Study: 
The aim of this project is to produce a basic protein map of breast tissue, be it 
cancerous or otherwise normal. The researchers of this proposed study seek firstly, to 
look at differences in known biological markers of breast cancer between two 
populations of women, one group from Greece and the other from Australia. Women 
from Mediterranean regions have a much lower mortality rate for breast cancer when 
compared to those in Australia. It has been suggested that environmental and/or 
dietary factors may account for this observation but as yet there is no data to clearly 
indicate that this is the case. If biological differences between these groups do exist, 
then these might present as higher or lower levels of known biological markers of the 
disease. 
The second part of the study uses a state of the art separation method that allows 
complex mixtures of molecules to be resolved. Using this method a biological map of 
all the molecules that make up a piece of tissue, such as a breast cancer, can be 
separated to produce a map, which is unique for that tissue. Normal breast tissue (e.g. 
from women undergoing breast reduction) would thus have a different map to breast 
cancer or for that matter advanced cancers that have broken away from the main 
breast tumour and begun to grow in another region of the body. The differences 
between maps for the normal breast tissue compared with cancerous tissue may 
represent molecules that have been generated as a result of the cancer. These 
molecules could be markers of the disease or targets for future vaccines or 
pharmaceutical drugs. 
Inclusion or exclusion criteria for this research project: 
This study includes patients who are either having a breast cancer removed, including 
any advanced cancers that have spread to the lymph nodes and women under going 
breast reduction surgery. There are no exclusion criteria for this project. 
Participation and withdrawal from the research project: 
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Participation in this research project is entirely voluntary and no financial payment 
will be given. If you decide to take part in this study, there will be no prejudice 
against your future care if you decide to withdraw prior to surgery. 
Confidentiality: 
Information and materials obtained during this project will remain strictly confidential 
and shall only be used for the purposes of this study. Only the investigators directly 
involved in this project will have access to identifying data. The Privacy Act, 1988 
gives this research project the guidelines for conduct. Your consent to participate in 
this research project will be an informed one and the investigator will answer any 
questions you have. Any unused tissue may be kept for future analysis in relation to 
this study alone, and will be disposed of in a professional manner when no longer 
required. 
Information Sheet and Consent Form: 
Copies of the information Sheet and signed consent forms will be given to you to 
keep. 
For more information about this research project, you can contact: 
Dr Roger Lord 
Discipline of Surgery 
GPO Box 252-28 Hobart 
Tasmania 7001 Australia 
Tel (03) 6226 4896 
Email: John.Lord@utas.edu.au 
Dr Kiron Bhatia 
Discipline of Surgery 
GPO Box 252C-28 Hobart 
Tasmania 7000 Australia 
Tel (03) 6226 4875 
Email: kdbhatia@postoffice.utas.edu.au  
If you have any concerns of an ethical nature or complaints about the manner in 
which the project is conducted, you may contact the chair of the Ethics 
Committee: 
Dr Rosalie Parton 
6222 8226 
or 
Chris Hooper 
Secretary, RHH ethics committee 
6226 2763 
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